Mirion (MIR) 10-Q 1 May 24 2024 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2024	Apr. 26, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-39352
Entity Registrant Name	Mirion Technologies, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	83-0974996
Entity Address, Address Line One	1218 Menlo Drive
Entity Address, City or Town	Atlanta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30318
City Area Code	770
Local Phone Number	432-2744
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Fiscal Period Focus	Q1
Amendment Flag	false
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0001809987
Class A Common Stock
Document Information [Line Items]
Title of 12(b) Security	Class A Common Stock, $0.0001 par value per share
Trading Symbol	MIR
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		220,159,325
Warrant
Document Information [Line Items]
Title of 12(b) Security	Redeemable warrants, each exercisable for one share of Class A common stock at an exercise price of $11.50
Trading Symbol	MIR WS
Security Exchange Name	NYSE
Class B Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		7,209,706

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 120.2	$ 128.8
Restricted cash	0.4	0.6
Accounts receivable, net of allowance for doubtful accounts	146.1	172.3
Costs in excess of billings on uncompleted contracts	62.6	48.7
Inventories	146.8	144.1
Prepaid expenses and other current assets	38.5	44.1
Total current assets	514.6	538.6
Property, plant, and equipment, net	138.3	134.5
Operating lease right-of-use assets	31.1	32.8
Goodwill	1,440.2	1,447.6
Intangible assets, net	504.3	538.8
Restricted cash	1.1	1.1
Other assets	19.1	25.1
Total assets	2,648.7	2,718.5
Current liabilities:
Accounts payable	53.1	58.7
Deferred contract revenue	95.8	103.4
Third-party debt, current	0.1	1.2
Operating lease liability, current	6.6	6.8
Accrued expenses and other current liabilities	79	95.6
Total current liabilities	234.6	265.7
Third-party debt, non-current	685.3	684.7
Warrant liabilities	61	55.3
Operating lease liability, non-current	26.5	28.1
Deferred income taxes, non-current	77.3	84
Other liabilities	46.1	50.7
Total liabilities	1,130.8	1,168.5
Commitments and contingencies (Note 10)
Stockholders’ equity (deficit):
Treasury stock, at cost; $— shares at March 31, 2024 and December 31, 2023	(1.3)	(1.3)
Additional paid-in capital	2,063.9	2,056.5
Accumulated deficit	(531.2)	(505.4)
Accumulated other comprehensive loss	(74.2)	(65.3)
Mirion Technologies, Inc. stockholders’ equity	1,457.2	1,484.5
Noncontrolling interests	60.7	65.5
Total stockholders’ equity	1,517.9	1,550
Total liabilities and stockholders’ equity	2,648.7	2,718.5
Class A Common Stock
Stockholders’ equity (deficit):
Common stock par value $0.001	0	0
Class B Common Stock
Stockholders’ equity (deficit):
Common stock par value $0.001	$ 0	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Common stock, shares outstanding (in shares)	18,750,000
Treasury stock, common (in shares)	149,076	149,076
Class A Common Stock
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)		500,000,000
Common stock, shares issued (in shares)	218,735,333	218,177,832
Common stock, shares outstanding (in shares)	218,735,333	218,177,832
Class B Common Stock
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	7,326,423	7,787,333
Common stock, shares outstanding (in shares)	7,326,423	7,787,333

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 192.6	$ 182.1
Cost of revenues:
Total cost of revenues	105.5	103
Gross profit	87.1	79.1
Operating expenses:
Selling, general and administrative	84.1	85.1
Research and development	7.9	7.6
Total operating expenses	92	92.7
Loss from operations	(4.9)	(13.6)
Other expense (income):
Interest expense	15.5	16
Interest income	(1.7)	(1.1)
Loss on debt extinguishment	0	2.6
Foreign currency loss (gain), net	0.8	(0.3)
Increase in fair value of warrant liabilities	5.7	13.4
Other expense (income), net	0.1	(0.2)
Loss before income taxes	(25.3)	(44)
Loss (benefit) from income taxes	1.2	(1.1)
Net loss	(26.5)	(42.9)
Loss attributable to noncontrolling interests	(0.7)	(1)
Net loss attributable to Mirion Technologies, Inc.	$ (25.8)	$ (41.9)
Net loss per common share attributable to Mirion Technologies, Inc. — basic (in dollars per share)	$ (0.13)	$ (0.22)
Net loss per common share attributable to Mirion Technologies, Inc. — diluted (in dollars per share)	$ (0.13)	$ (0.22)
Weighted average common shares outstanding — basic (in shares)	199,729	187,701
Weighted average common shares outstanding — diluted (in shares)	199,729	187,701
Product
Revenues:
Total revenues	$ 140	$ 132.4
Cost of revenues:
Total cost of revenues	79	76.8
Service
Revenues:
Total revenues	52.6	49.7
Cost of revenues:
Total cost of revenues	$ 26.5	$ 26.2

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Net loss	$ (26.5)	$ (42.9)
Foreign currency translation (loss) gain, net of tax	(14.7)	10.6
Unrealized gain (loss) on net investment hedges, net of tax	4.9	(2.3)
Unrealized gain on cash flow hedge, net of tax	0.6	0
Other comprehensive (loss) income, net of tax	(9.2)	8.3
Comprehensive loss	(35.7)	(34.6)
Less: Comprehensive loss attributable to noncontrolling interest	(1)	(0.7)
Comprehensive loss attributable to Mirion Technologies, Inc.	$ (34.7)	$ (33.9)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders’ Equity - USD ($) $ in Millions	Total	Conversion of shares of class B common stock to class A common stock	Class A Common Stock	Class B Common Stock	Common Stock Class A Common Stock	Common Stock Class A Common Stock Conversion of shares of class B common stock to class A common stock	Common Stock Class B Common Stock	Common Stock Class B Common Stock Conversion of shares of class B common stock to class A common stock	Treasury Stock	Additional Paid-In Capital	Additional Paid-In Capital Conversion of shares of class B common stock to class A common stock	Accumulated Deficit	Accumulated Other Comprehensive (Loss) Income	Noncontrolling Interests	Noncontrolling Interests Conversion of shares of class B common stock to class A common stock
Beginning balance (in shares) at Oct. 19, 2021			9,976,164
Ending balance (in shares) at Oct. 20, 2021			18,750,000	18,750,000
Beginning balance (in shares) at Dec. 31, 2022					200,298,834		8,040,540
Beginning balance at Dec. 31, 2022	$ 1,467.2				$ 0		$ 0		$ 0	$ 1,882.4		$ (408.5)	$ (75.7)	$ 69
Beginning balance (in shares) at Dec. 31, 2022									0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issued, conversion of convertible securities (in shares)					100	193,207		(193,207)
Stock issued for vested restricted stock units (in shares)					40,764
Stock compensation to directors in lieu of cash compensation (in shares)					12,090
Stock compensation to directors in lieu of cash compensation	0.1									0.1
Conversion of shares of class B common stock to class A common stock		$ 0									$ 1.6				$ (1.6)
Issuance of shares of class A common stock, net of offering costs (in shares)					17,142,857
Issuance of shares of class A common stock, net of offering costs	149.8									149.8
Stock-based compensation expense	5.5									5.5
Net loss	(42.9)											(41.9)		(1)
Other comprehensive income	8.3												8	0.3
Ending balance (in shares) at Mar. 31, 2023					217,687,852		7,847,333
Ending balance at Mar. 31, 2023	1,588				$ 0		$ 0		$ 0	2,039.4		(450.4)	(67.7)	66.7
Ending balance (in shares) at Mar. 31, 2023									0
Beginning balance (in shares) at Dec. 31, 2023			218,177,832	7,787,333	218,177,832		7,787,333
Beginning balance at Dec. 31, 2023	$ 1,550				$ 0		$ 0		$ (1.3)	2,056.5		(505.4)	(65.3)	65.5
Beginning balance (in shares) at Dec. 31, 2023	149,076								149,076
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issued, conversion of convertible securities (in shares)						460,910		(460,910)
Stock issued for vested restricted stock units (in shares)					88,171
Stock compensation to directors in lieu of cash compensation (in shares)					8,420
Stock compensation to directors in lieu of cash compensation	$ 0.1									0.1
Conversion of shares of class B common stock to class A common stock		$ 0									$ 3.8				$ (3.8)
Stock-based compensation expense	3.5									3.5
Net loss	(26.5)											(25.8)		(0.7)
Other comprehensive income	$ (9.2)												(8.9)	(0.3)
Ending balance (in shares) at Mar. 31, 2024	18,750,000		218,735,333	7,326,423	218,735,333		7,326,423
Ending balance at Mar. 31, 2024	$ 1,517.9				$ 0		$ 0		$ (1.3)	$ 2,063.9		$ (531.2)	$ (74.2)	$ 60.7
Ending balance (in shares) at Mar. 31, 2024	149,076								149,076

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
OPERATING ACTIVITIES:
Net loss	$ (26.5)	$ (42.9)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization expense	38.8	41.3
Stock-based compensation expense	3.6	5.5
Amortization of debt issuance costs	0.7	3.5
Provision for doubtful accounts	0.8	0.8
Inventory obsolescence write down	1.2	1
Change in deferred income taxes	(7.5)	(7.1)
Loss on disposal of property, plant and equipment	0.3	0.8
Loss (gain) on foreign currency transactions	0.8	(0.3)
Increase in fair values of warrant liabilities	5.7	13.4
Changes in operating assets and liabilities:
Accounts receivable	24.2	19.1
Costs in excess of billings on uncompleted contracts	(8.2)	(8.6)
Inventories	(5.6)	(13.9)
Prepaid expenses and other current assets	4.2	(0.3)
Accounts payable	(5.4)	(2.5)
Accrued expenses and other current liabilities	(12.3)	(8.5)
Deferred contract revenue and liabilities	(9.1)	(3.6)
Other assets	(0.2)	0.4
Other liabilities	0.5	(0.8)
Net cash provided by (used in) operating activities	6	(2.7)
INVESTING ACTIVITIES:
Acquisitions of businesses, net of cash and cash equivalents acquired	(1)	0
Purchases of property, plant, and equipment and badges	(12.8)	(7.5)
Proceeds from net investment hedge derivative contracts	0.9	0
Net cash used in investing activities	(12.9)	(7.5)
FINANCING ACTIVITIES:
Issuances of common stock	0	150
Common stock issuance costs	0	(0.2)
Principal repayments	0	(125)
Proceeds from net cash flow hedge derivative contracts	0.3	0
Other financing	(0.1)	(0.2)
Net cash provided by financing activities	0.2	24.6
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(2.1)	0.7
Net (decrease) increase in cash, cash equivalents, and restricted cash	(8.8)	15.1
Cash, cash equivalents, and restricted cash at beginning of period	130.5	75
Cash, cash equivalents, and restricted cash at end of period	$ 121.7	$ 90.1

Nature of Business and Summary

Nature of Business and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Nature of Business and Summary of Significant Accounting Policies	Nature of Business and Summary of Significant Accounting Policies Nature of Business Mirion Technologies, Inc. (“Mirion,” the “Company," "we," "our," or "us" and formerly GS Acquisition Holdings Corp II ("GSAH")) is a global provider of radiation detection, measurement, analysis, and monitoring products and services to the medical, nuclear, and defense end markets. On October 20, 2021, Mirion Technologies, Inc. was formed (formerly known as GS Acquisition Holdings Corp II or "GSAH") when it consummated its business combination with GSAH (the "Business Combination") pursuant to the Business Combination Agreement dated June 17, 2021. We provide products and services through our two operating and reportable segments; (i) Medical and (ii) Technologies. The Medical segment provides radiation oncology quality assurance, delivering patient safety solutions for diagnostic imaging and radiation therapy centers around the world, dosimetry solutions for monitoring the total amount of radiation medical staff members are exposed to over time, radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy, and radionuclide therapy products for nuclear medicine applications such as shielding, product handling, medical imaging furniture, and rehabilitation products. The Technologies segment provides robust, field ready personal radiation detection and identification equipment for defense applications and radiation detection and analysis tools for power plants, labs, and research applications. Nuclear power plant product offerings are used for the full nuclear power plant lifecycle including core detectors and essential measurement devices for new build, maintenance, decontamination and decommission equipment for monitoring and control during fuel dismantling and remote environmental monitoring. The Company is headquartered in Atlanta, Georgia and has operations in the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, the Netherlands, Estonia, and Japan. Basis of Presentation and Principles of Consolidation The accompanying unaudited Condensed Consolidated Financial Statements and Notes to Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for financial statements and pursuant to the accounting and disclosure rules and regulations of the U.S. Securities and Exchange Commission (the "SEC") for interim financial information. The interim unaudited Condensed Consolidated Financial Statements reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair representation of the results for the periods presented and should be read in conjunction with the audited Consolidated Financial Statements and notes thereto for the period ended December 31, 2023, which include a complete set of footnote disclosures, including our significant accounting policies included in our Annual Report on Form 10-K. The results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned and majority-owned or controlled subsidiaries. For consolidated subsidiaries where our ownership is less than 100%, the portion of the net income or loss allocated to noncontrolling interests is reported as “Income (Loss) attributable to noncontrolling interests” in the unaudited Condensed Consolidated Statements of Operations. All intercompany accounts and transactions have been eliminated in consolidation. The Company recognizes a noncontrolling interest for the portion of Class B common stock of IntermediateCo that is not attributable to the Company. See Note 20, Noncontrolling Interests. Segments The Company manages its operations through two operating and reportable segments: Medical and Technologies (formerly known as Industrial). These segments align the Company’s products and service offerings with customer use in medical and industrial markets and are consistent with how the Company’s Chief Executive Officer, its Chief Operating Decision Maker (“CODM”), reviews and evaluates the Company’s operations. The CODM allocates resources and evaluates the financial performance of each operating segment. The Company’s segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Refer to Note 15, Segment Information , for further detail. Use of Estimates Management estimates and judgments are an integral part of financial statements prepared in accordance with GAAP. We believe that the critical accounting policies listed below address the more significant estimates required of management when preparing our consolidated financial statements in accordance with GAAP. We consider an accounting estimate critical if changes in the estimate may have a material impact on our financial condition or results of operations. We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, actual results could differ from the original estimates, requiring adjustment to these balances in future periods. The accounting policies that reflect our more significant estimates, judgments and assumptions and which we believe are the most critical to aid in fully understanding and evaluating our reported financial results include but are not limited to: business combinations, goodwill and intangible assets; estimated progress toward completion for certain revenue contracts; uncertain tax positions and tax valuation allowances and derivative warrant liabilities. Significant Accounting Policies Accounts Receivable and Allowance for Doubtful Accounts The allowance for doubtful accounts is based on the Company’s assessment of the collectability of customer accounts. The allowance for doubtful accounts was $8.1 million and $7.8 million as of March 31, 2024 and December 31, 2023, respectively. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets are primarily comprised of various prepaid assets including prepaid insurance, short-term marketable securities, and income tax receivables. The components of prepaid expenses and other current assets consist of the following (in millions): March 31, 2024 December 31, 2023 Prepaid insurance $ 2.3 $ 1.0 Prepaid vendor deposits 7.3 7.6 Prepaid software licenses 3.9 3.5 Short-term marketable securities 5.4 5.3 Income tax receivable and prepaid income taxes 1.0 8.0 Other tax receivables 1.4 1.4 Other current assets 17.2 17.3 $ 38.5 $ 44.1 Facility and Equipment Decommissioning Liabilities The Company has asset retirement obligations (“ARO”) consisting primarily of equipment and facility decommissioning costs. ARO liabilities totaled $2.3 million for both periods ended March 31, 2024 and December 31, 2023, and were included in accrued expenses and other current liabilities and other liabilities on the unaudited Condensed Consolidated Balance Sheets. Accretion expense related to these liabilities was not material for any periods presented. Revenue Recognition The Company recognizes revenue from arrangements that include performance obligations to design, engineer, manufacture, deliver, and install products. If a performance obligation does not qualify for over-time revenue recognition, revenue is then recognized at the point-in-time in which control of the distinct good or service is transferred to the customer, typically based upon the terms of delivery. Revenue derived from passive dosimetry and analytical services is of a subscription nature and is provided to customers on an agreed-upon recurring monthly, quarterly or annual basis. Revenue is recognized ratably over the service period as the service is continuous, and no other discernible pattern of recognition is evident. Contract Balances The timing of the Company's revenue recognition, invoicing, and cash collections results in accounts receivable, costs and estimated earnings in excess of billings on uncompleted contracts, and deferred contract revenue. Refer to Note 4, Contracts in Progress for further details. Remaining Performance Obligations The remaining performance obligations for all open contracts as of March 31, 2024 include assembly, delivery, installation, and trainings. The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts was approximately $840.5 million and $857.1 million as of March 31, 2024 and December 31, 2023, respectively. As of March 31, 2024, the Company expects to recognize approximately 45%, 25%, 12%, and 10% of the remaining performance obligations as revenue during the fiscal years 2024, 2025, 2026 and 2027, respectively, and the remainder thereafter. Disaggregation of Revenues A disaggregation of the Company’s revenues by segment, geographic region, timing of revenue recognition and product category is provided in Note 15, Segment Information . Warrant Liability As of March 31, 2024, the Company had outstanding warrants to purchase up to 27,249,779 shares of Class A common stock. Th e Company accounts for the warrants in accordance with the guidance contained in ASC 815, “Derivatives and Hedging”, under which the warrants do not meet the criteria for equity treatment and must be recorded as derivative liabilities. Accordingly, the Company classifies the warrants as liabilities at their fair value and adjusts the warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until the warrants are exercised or expire, and any change in fair value is recognized in the Company’s unaudited Condensed Consolidated Statements of Operations. The fair value of the warrants (the "Public Warrants") issued in connection with GSAH's initial public offering has been measured based on the listed market price of such Public Warrants. As the transfer of certain warrants issued in a private placement (the "Private Placement Warrants") to GS Sponsor II LLC, the sponsor of GSAH (the "Sponsor"), to anyone who is not a permitted transferee would result in the Private Placement Warrants having substantially the same terms as the Public Warrants, we determined that the fair value of each Private Placement Warrant is equivalent to that of each Public Warrant. The determination of the fair value of the warrant liability may be subject to change as more current information becomes available and accordingly the actual results could differ significantly. Derivative warrant liabilities are classified as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. See Note 16, Fair Value Measurements . On April 18, 2024, the Company announced that it will redeem all Public Warrants that remain outstanding at 5:00 pm New York City time on Monday, May 20, 2024, for a redemption price of $0.10 per warrant. See Note 22, Subsequent Events . Treasury Stock We account for treasury stock under the cost method pursuant to the provisions of ASC 505-30, Treasury Stock. Under the cost method, the gross cost of the shares reacquired is charged to a contra equity account, treasury stock. The equity accounts that were originally credited for the original share issuance, Common Stock and additional paid-in capital, remain intact. If the treasury shares are ever reissued in the future at a price higher than its cost, the difference is recorded as a component of additional paid-in-capital in the unaudited Condensed Consolidated Balance Sheets. When treasury stock is re-issued at a price lower than its cost, the difference is recorded as a component of additional paid-in-capital to the extent that there are previously recorded gains to offset the losses. If there are no treasury stock gains in additional paid-in-capital, the losses upon re-issuance of treasury stock are recorded as a reduction of retained earnings in the unaudited Condensed Consolidated Balance Sheets. If treasury stock is reissued in the future, a cost flow assumption (e.g., FIFO, LIFO or specific identification) will be adopted to compute excesses and deficiencies upon subsequent share reissuance. Concentrations of Risk Financial instruments that are potentially subject to concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company maintains cash in bank deposit accounts that, at times, may exceed the insured limits of the local country. The Company has not experienced any losses in such accounts. The Company sells its products and services mainly to large, private and governmental organizations in the Americas, Europe, the Middle East and Asia Pacific regions. The Company performs ongoing evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary. The Company generally does not require its customers to provide collateral or other security to support accounts receivable. As of March 31, 2024 and December 31, 2023, no customer accounted for more than 10% of the accounts receivable balance. Recent Accounting Pronouncements Accounting Guidance Issued But Not Yet Adopted In October 2023, the FASB issued ASU 2023-06 “Disclosure Improvements”. ASU 2023-06 clarifies or improves disclosure and presentation requirements of a variety of topics. For entities subject to the SEC’s existing disclosure requirements, the effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. For all entities, if by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the codification and will not become effective for any entity. The Company is currently evaluating the impact of this ASU.

Business Combinations and Acqui

Business Combinations and Acquisitions	3 Months Ended
	Mar. 31, 2024
Business Combination and Asset Acquisition [Abstract]
Business Combinations and Acquisitions	Business Combinations and Acquisitions The Company continually evaluates potential acquisitions that strategically fit with the Company’s existing portfolio. On November 1, 2023, Mirion closed the acquisition of ec 2 Software Solutions, LLC and NUMA LLC (collectively "ec 2 ") with a purchase price of $31.4 million in a taxable transaction pursuant to an asset purchase agreement dated November 1, 2023 between Mirion and ec 2 . As part of the Mirion Medical segment, ec 2 will complement the Nuclear Medicine and Molecular Imaging portfolio of Capintec. The total business enterprise value acquired for the ec 2 acquisition was comprised of $14.5 million of intangible assets related to technology, trade name, and customer list, $17.4 million of goodwill and $0.5 million of liabilities mainly related to deferred revenue. Measurement period adjustments to the previously disclosed preliminary fair value of net assets related to ec2 were recorded in 2024, resulting in a $0.6 million net increase in goodwill, primarily due to additional consideration of $1.0 million (final net working capital adjustment) and a $0.3 million net increase in intangible assets during the three months ended March 31, 2024. The estimated fair values of all assets acquired and liabilities assumed in the acquisition are provisional and may be revised as a result of additional information obtained during the measurement period of up to one year from the acquisition date, including but not limited to deferred revenue balances and the valuation of tax accounts. Transaction costs related to ec 2 were not material for the three months ended March 31, 2024. All acquisitions are accounted for under the acquisition method of accounting, and the related assets acquired and liabilities assumed are recorded at fair value. The Company makes an initial allocation of the purchase price at the date of acquisition based upon its understanding of the fair value of the acquired assets and assumed liabilities. The Company obtains the information used for the purchase price allocation during due diligence and through other sources. In the months after closing, as the Company obtains additional information about the acquired assets and liabilities, including through tangible and intangible asset appraisals, and learns more about the newly acquired business, it is able to refine the estimates of fair value and more accurately allocate the purchase price. The fair values of acquired intangibles are determined based on estimates and assumptions that are deemed reasonable by the Company. Significant assumptions include the discount rates and certain assumptions that form the basis of the forecasted results of the acquired business including revenue, earnings before interest, taxes, depreciation and amortization (“EBITDA”), and growth rates. These assumptions are forward looking and could be affected by future economic and market conditions. Only facts and circumstances that existed as of the acquisition date are considered for subsequent adjustment. The Company will make appropriate adjustments to the purchase price allocation prior to completion of the measurement period, as required. Purchases of acquired businesses resulted in the recognition of goodwill in the Company’s Consolidated Financial Statements, which is calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. The goodwill is not amortized but some portion may be deductible for income tax purposes. This goodwill recorded includes the following: • The expected synergies and other benefits that we believe will result from combining the operations of the acquired business with the operations of Mirion; • Any intangible assets that did not qualify for separate recognition, as well as future, yet unidentified projects and products; • The value of the existing business as an assembled collection of net assets versus if the Company had acquired all of the net assets separately.

Contracts in Progress

Contracts in Progress	3 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Contracts in Progress	Contracts in Progress Costs and billings on uncompleted construction-type contracts consist of the following (in millions): March 31, 2024 December 31, 2023 Costs incurred on contracts (from inception to completion) $ 353.1 $ 324.5 Estimated earnings 211.8 208.7 Contracts in progress 564.9 533.2 Less: billings to date (524.3) (511.3) $ 40.6 $ 21.9 The carrying amounts related to uncompleted construction-type contracts are included in the accompanying unaudited Condensed Consolidated Balance Sheets under the following captions (in millions): March 31, 2024 December 31, 2023 Costs and estimated earnings in excess of billings on uncompleted contracts – current $ 62.6 $ 48.7 Costs and estimated earnings in excess of billings on uncompleted contracts – non-current (1) 11.3 18.2 Billings in excess of costs and estimated earnings on uncompleted contracts – current (2) (31.5) (41.1) Billings in excess of costs and estimated earnings on uncompleted contracts – non-current (3) (1.8) (3.9) $ 40.6 $ 21.9 (1) Included in other assets within the Condensed Consolidated Balance Sheets. (2) Included in deferred contract revenue – current within the Condensed Consolidated Balance Sheets. (3) Included in other liabilities within the Condensed Consolidated Balance Sheets. For the three months ended March 31, 2024 the Company has recognized revenue of $17.6 million related to the contract liabilities balance as of December 31, 2023.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2024
Inventory Disclosure [Abstract]
Inventories	Inventories The components of inventories consist of the following (in millions): March 31, 2024 December 31, 2023 Raw materials $ 66.5 $ 67.2 Work in progress 36.7 35.3 Finished goods 43.6 41.6 $ 146.8 $ 144.1

Property, Plant, and Equipment,

Property, Plant, and Equipment, Net	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Property, Plant, and Equipment, Net	Property, Plant and Equipment, Net Property, plant and equipment, net consist of the following (in millions): Depreciable March 31, 2024 December 31, 2023 Land, buildings, and leasehold improvements 3-39 years $ 49.9 $ 49.4 Machinery and equipment 5-15 years 39.6 38.5 Badges 3-5 years 44.2 41.0 Furniture, fixtures, computer equipment and other 3-10 years 22.9 22.9 Software development costs 3-5 years 11.0 10.7 Construction in progress (1) — 32.5 28.6 200.1 191.1 Less: accumulated depreciation and amortization (61.8) (56.6) $ 138.3 $ 134.5 (1) Includes $5.6 million and $4.2 million of Construction in progress for internally developed software as of March 31, 2024, and December 31, 2023, respectively. Total depreciation expense included in costs of revenues and operating expenses was as follows (in millions): Three Months Ended Three Months Ended March 31, 2024 March 31, 2023 Depreciation expense in: Cost of revenues $ 5.3 $ 4.7 Operating expenses $ 2.0 $ 2.9

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2024
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following (in millions): March 31, 2024 December 31, 2023 Compensation and related benefit costs $ 34.7 $ 41.8 Customer deposits 8.0 8.5 Accrued commissions 0.3 0.3 Accrued warranty costs 4.9 4.5 Non-income taxes payable 9.2 11.8 Pension and other post-retirement obligations 0.3 0.3 Income taxes payable 2.7 4.2 Derivative liability 7.7 10.7 Other accrued expenses 11.2 13.5 Total $ 79.0 $ 95.6

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill Goodwill is calculated as the excess of consideration transferred over the net assets recognized for acquired businesses and represents future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. Goodwill is assigned to reporting units at the date the goodwill is initially recorded and is reallocated as necessary based on the composition of reporting units over time. The Company assesses goodwill for impairment at the reporting unit level annually on the first day of the fourth quarter and upon the occurrence of a triggering event or change in circumstance that would more likely than not reduce the fair value of a reporting unit below its carrying amount. A quantitative test performed upon the occurrence of a triggering event compares the fair value of a reporting unit with its carrying amount. The Company determines fair values for each of the reporting units, as applicable, using the market approach, when available and appropriate, or the income approach, or a combination of both. The Company assesses the valuation methodology based upon the relevance and availability of the data at the time the Company performs the valuation. If multiple valuation methodologies are used, the results are weighted appropriately. Valuations using the market approach are derived from metrics of publicly traded companies or historically completed transactions of comparable businesses. The selection of comparable businesses is based on the markets in which the reporting units operate giving consideration to risk profiles, size, geography, and diversity of products and services. A market approach is limited to reporting units for which there are publicly traded companies that have characteristics similar to the Company's businesses. Under the income approach, fair value is determined based on the present value of estimated future cash flows, discounted at an appropriate risk-adjusted rate. The Company uses its internal forecasts to estimate future cash flows and include an estimate of long-term future growth rates based on our most recent views of the long-term outlook for each business. Actual results may differ from those assumed in the forecasts. The Company derives its discount rates using a capital asset pricing model and by analyzing published rates for industries relevant to its reporting units to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in internally developed forecasts. No goodwill impairment was recognized for the three months ended March 31, 2024 and March 31, 2023, respectively. The following table shows changes in the carrying amount of goodwill by reportable segment as of March 31, 2024 and December 31, 2023 (in millions): Medical Technologies Consolidated Balance—December 31, 2023 $ 633.4 $ 814.2 $ 1,447.6 Measurement period adjustment 0.6 — 0.6 Translation adjustment — (8.0) (8.0) Balance—March 31, 2024 $ 634.0 $ 806.2 $ 1,440.2 A portion of goodwill is deductible for income tax purposes. Gross carrying amounts and cumulative goodwill impairment losses are as follows (in millions): March 31, 2024 December 31, 2023 Gross Carrying Amount Cumulative Impairment Gross Carrying Amount Cumulative Impairment Goodwill $ 1,652.0 $ (211.8) $ 1,659.4 $ (211.8) Intangible Assets Intangible assets consist of our developed technology, customer relationships, backlog, trade names, and non-compete agreements at the time of acquisition through business combinations. The customer relationships definite lived intangible assets are amortized using the double declining balance method while all other definite lived intangible assets are amortized on a straight-line basis over their estimated useful lives. Many of our intangible assets are not deductible for income tax purposes. A summary of intangible assets useful lives, gross carrying value and related accumulated amortization is below (in millions): March 31, 2024 Original Average Gross Carrying Accumulated Net Book Customer relationships 6 - 13 $ 339.2 $ (155.8) $ 183.4 Distributor relationships 7 - 13 60.9 (17.8) 43.1 Developed technology 5 - 16 262.3 (75.1) 187.2 Trade names 3 - 10 99.0 (24.4) 74.6 Backlog and other 1 - 4 75.2 (59.2) 16.0 Total $ 836.6 $ (332.3) $ 504.3 December 31, 2023 Original Average Gross Carrying Accumulated Net Book Customer relationships 6 - 13 $ 340.8 $ (143.1) $ 197.7 Distributor relationships 7 - 13 60.9 (16.0) 44.9 Developed technology 5 - 16 264.1 (67.8) 196.3 Trade names 3 - 10 99.7 (22.1) 77.6 Backlog and other 1 - 4 76.0 (53.7) 22.3 Total $ 841.5 $ (302.7) $ 538.8 Aggregate amortization expense for intangible assets included in cost of revenues and operating expenses was as follows (in millions): Three Months Ended March 31, Three Months Ended March 31, 2024 2023 Amortization expense for intangible assets in: Cost of revenues $ 6.8 $ 6.7 Operating expenses $ 24.7 $ 26.9

Borrowings

Borrowings	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Borrowings	Borrowings Third-party debt consist of the following (in millions): March 31, 2024 December 31, 2023 2021 Credit Agreement $ 694.6 $ 694.6 Canadian Financial Institution 1.0 1.0 Other 1.7 2.8 Total third-party debt 697.3 698.4 Less: third-party debt, current (0.1) (1.2) Less: deferred financing costs (11.8) (12.5) Third-party debt, non-current $ 685.4 $ 684.7 As of March 31, 2024 and December 31, 2023, the fair market value of the Company's 2021 Credit Agreement (defined below) was $695.5 million. The fair market value for the 2021 Credit Agreement was estimated using primarily level 2 inputs, including borrowing rates available to the Company at the respective period ends. The fair market value for the Company’s remaining third-party debt approximates the respective carrying amounts as of March 31, 2024 and December 31, 2023. 2021 Credit Agreement In connection with the Business Combination, certain subsidiaries of the Company entered into the 2021 Credit Agreement with the lending institutions party thereto (as amended, restated, supplemented, or otherwise modified from time to time, the "2021 Credit Agreement"). The 2021 Credit Agreement refinanced and replaced the credit agreement from March 2019, by and between, among others, Mirion Technologies (HoldingRep), Ltd., its subsidiaries and Morgan Stanley Senior Funding Inc., as administrative agent, certain other revolving lenders and a syndicate of institutional lenders (the “2019 Credit Facility”). The 2021 Credit Agreement provides for an $830.0 million senior secured first lien term loan facility and a $90.0 million senior secured revolving facility (collectively, the “Credit Facilities”). Funds from the Credit Facilities are permitted to be used in connection with the Business Combination and related transactions to refinance the 2019 Credit Facility referred to above and for general corporate purposes. The term loan facility is scheduled to mature on October 20, 2028 and the revolving facility is scheduled to expire and mature on October 20, 2026. The agreement requires the payment of a commitment fee of 0.50% per annum for unused revolving commitments, subject to stepdowns to 0.375% per annum and 0.25% per annum upon the achievement of specified leverage ratios. Any outstanding letters of credit issued under the 2021 Credit Agreement reduce the availability under the revolving line of credit. The 2021 Credit Agreement is secured by a first priority lien on the equity interests of the Parent Borrower owned by Holdings and substantially all of the assets (subject to customary exceptions) of the borrowers and the other guarantors thereunder. Interest with respect to the facilities is based on, at the option of the borrowers, (i) a customary base rate formula for borrowings in U.S. dollars or (ii) a floating rate formula based on LIBOR (with customary fallback provisions) for borrowings in U.S. dollars, a floating rate formula based on Euro Interbank Offered Rate ("EURIBOR") for borrowings in Euro or a floating rate formula based on SONIA for borrowings in Pounds Sterling, each as described in the 2021 Credit Agreement with respect to the applicable type of borrowing. The 2021 Credit Agreement includes fallback language that seeks to either facilitate an agreement with the Company's lenders on a replacement rate for LIBOR in the event of its discontinuance or that automatically replaces LIBOR with benchmark rates based upon the Secured Overnight Financing Rate ("SOFR") or other benchmark replacement rates upon certain triggering events. On June 23, 2023, the 2021 Credit Agreement was amended to replace the interest rate based on the London interbank offered rate (“LIBOR”) and related LIBOR-based mechanics applicable to U.S. Dollar borrowings under the Existing Credit Agreement with an interest rate based on SOFR and related SOFR-based mechanics. On December 30, 2023, certain subsidiaries of Mirion Technologies, Inc. and Citibank, N.A., as administrative agent and collateral agent, entered into a Holdings Assumption Agreement (the “Holdings Assumption Agreement”) and related collateral and guarantee joinder documents that supplemented and modified the 2021 Credit Agreement. Pursuant to the terms of the Holdings Assumption Agreement, Mirion Technologies (HoldingSub2), Ltd., a limited liability company incorporated in England and Wales (“HoldingSub2”), assigned to Mirion IntermediateCo, Inc., a Delaware corporation (“IntermediateCo”) and a subsidiary of the Company, all of its rights, obligations and liabilities in and under the 2021 Credit Agreement, including its obligations to guarantee certain obligations of the borrowers under the 2021 Credit Agreement and to pledge certain assets. After giving effect to the Holdings Assumption Agreement, HoldingSub2 was released from all of its obligations and liabilities as “Holdings” under the Existing Credit Agreement and the other credit documents, and IntermediateCo became party as “Holdings” to the Existing Credit Agreement and the other credit documents to which HoldingSub2 was a party as “Holdings” for all purposes. The 2021 Credit Agreement contains customary representations and warranties as well as customary affirmative and negative covenants and events of default. The negative covenants include, among others and in each case subject to certain thresholds and exceptions, limitations on incurrence of liens, limitations on incurrence of indebtedness, limitations on making dividends and other distributions, limitations on engaging in asset sales, limitations on making investments, and a financial covenant that the “First Lien Net Leverage Ratio” (as defined in the 2021 Credit Agreement) as of the end of any fiscal quarter is not greater than 7.00 to 1.00 if on the last day of such fiscal quarter certain borrowings outstanding under the revolving credit facility exceed 40% of the total revolving credit commitments at such time. The covenants also contain limitations on the activities of Mirion IntermediateCo, Inc. as the “passive” holding company. If any of the events of default occur and are not cured or waived, any unpaid amounts under the 2021 Credit Agreement may be declared immediately due and payable, the revolving credit commitments may be terminated and remedies against the collateral may be exercised. Mirion IntermediateCo, Inc. were in compliance with all debt covenants on March 31, 2024 and December 31, 2023. Term Loan - The term loan has a seven-year term (expiring October 2028) and bears interest at the greater of LIBOR (through June 30, 2023) / SOFR (subsequent to June 30, 2023) or 0.50%, plus 2.75%. No further principal payments are due until the expiration of the term. The interest rate was 8.36% and 8.40% (including spread rate based upon rate term) as of March 31, 2024 and December 31, 2023, respectively. The Company paid no principal payments and $127.1 million for the three months ended March 31, 2024 and for year ended December 31, 2023, respectively, yielding an outstanding balance of approximately $694.6 million for both periods ending March 31, 2024 and December 31, 2023. During the three months ended March 31, 2023, the Company used $125.0 million of proceeds received from a direct registered equity offering to pay down early outstanding amounts on the term loan. This payment satisfied the quarterly principal repayment requirement (0.25% of the original principal balance) such that no additional principal repayments are necessary until the expiration of the term loan. Revolving Line of Credit - The revolving line of credit arrangement has a five year term and bears interest at the greater of LIBOR (through June 30, 2023) / SOFR (subsequent to June 30, 2023) or 0%, plus 2.75%. The agreement requires the payment of a commitment fee of 0.25% per annum for unused commitments. The revolving line of credit matures in October 2026, at which time all outstanding revolving facility loans and accrued and unpaid interest are due. Any outstanding letters of credit reduce the availability of the revolving line of credit. There was no outstanding balance under the arrangement as of March 31, 2024 and December 31, 2023. Additionally, the Company has standby letters of credit issued under its 2021 Credit Agreement that reduce the availability under the revolver of $16.4 million for both period ended March 31, 2024 and December 31, 2023, respectively. The amount available on the revolver as of March 31, 2024 and December 31, 2023 was approximately $73.6 million. Deferred Financing Costs In connection with the issuance of the 2021 Credit Agreement term loan, we incurred debt issuance costs of $21.7 million on date of issuance. In accordance with accounting for debt issuance costs, we recognize and present deferred finance costs associated with non-revolving debt and financing obligations as a reduction from the face amount of related indebtedness in the unaudited Condensed Consolidated Balance Sheets. In connection with the issuance of the 2021 Credit Agreement revolving line of credit, we incurred debt issuance costs of $1.8 million. We recognize and present debt issuance costs associated with revolving debt arrangements as an asset and include the deferred finance costs within other assets in the unaudited Condensed Consolidated Balance Sheets. We amortize all debt issuance costs over the life of the related indebtedness. For the three months ended March 31, 2024 and March 31, 2023, we incurred approximately $0.7 million and $3.5 million (including a $2.6 million loss on debt extinguishment for the $125.0 million early debt repayment) of amortization expense of the deferred financing costs, respectively. Canadian Financial Institution - In May 2019, the Company entered into a credit agreement for C$1.7 million ($1.3 million) with a Canadian financial institution that matures in April 2039. The note bears annual interest at 4.69%. The credit agreement is secured by the facility acquired using the funds obtained. Overdraft Facilities The Company has overdraft facilities with certain German and French financial institutions. As of March 31, 2024 and December 31, 2023, there were no outstanding amounts under these arrangements. Accounts Receivable Sales Agreement We are party to agreements to sell short-term receivables from certain qualified customer trade accounts to an unaffiliated French financial institution and an unaffiliated Finnish financial institution without recourse. Under these agreements, the Company can sell up to €7.6 million ($8.2 million) and €12.3 million ($13.6 million) as of March 31, 2024 and December 31, 2023, respectively, of eligible accounts receivables. The accounts receivable under these agreements are sold at face value and are excluded from the consolidated balance if revenue has been recognized on the related receivable. When the related revenue has not been recognized on the receivable the Company considers the accounts receivable to be collateral for short-term borrowings. As of March 31, 2024 and December 31, 2023, there was no amount and approximately $1.0 million, respectively, outstanding under these arrangements included as Other in the Borrowings table above. Total costs associated with this arrangement were immaterial for all periods presented and are included in selling, general and administrative expense in the Condensed Consolidated Statements of Operations. Performance Bonds and Other Credit Facilities The Company has entered into various line of credit arrangements with local banks in France and Germany. These arrangements provide for the issuance of documentary and standby letters of credit of up to €77.1 million ($83.2 million) and €71.8 million ($79.3 million), as of March 31, 2024 and December 31, 2023, respectively, subject to certain local restrictions. As of March 31, 2024 and December 31, 2023, there were €54.9 million ($59.3 million) and €54.7 million ($60.4 million), respectively, of the lines that had been utilized to guarantee documentary and standby letters of credit, with interest rates ranging from 0.5% to 2.0%. In addition, the Company posts performance bonds with irrevocable letters of credit to support certain contractual obligations to customers for equipment delivery. These letters of credit are supported by restricted cash accounts, which totaled $1.5 million and $1.7 million as of March 31, 2024 and December 31, 2023, respectively. At March 31, 2024, contractual principal payments of total third-party borrowings are as follows (in millions): Remainder of 2024 $ 0.1 Fiscal year ending December 31: 2025 0.1 2026 1.7 2027 0.1 2028 694.7 Thereafter 0.6 Gross Payments 697.3 Unamortized debt issuance costs (11.8) Total third-party borrowings, net of debt issuance costs $ 685.5

Leased Assets

Leased Assets	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Leased Assets	Leased Assets The Company primarily leases certain logistics, office, and manufacturing facilities, as well as vehicles, copiers and other equipment. These operating leases generally have remaining lease terms between 1 month and 30 years, and some include options to extend (generally 1 to 10 years). The exercise of lease renewal options is at the Company’s discretion. The Company evaluates renewal options at lease inception and on an ongoing basis, and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. Lease agreements generally do not require material variable lease payments, residual value guarantees or restrictive covenants. The table below presents the locations of the operating lease assets and liabilities in the unaudited Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023, respectively (in millions): Balance Sheet Line Item March 31, 2024 December 31, 2023 Operating lease assets Operating lease right-of-use assets $ 31.1 $ 32.8 Financing lease assets Other assets $ 0.1 $ 0.1 Operating lease liabilities: Current operating lease liabilities Current operating lease liabilities $ 6.6 $ 6.8 Non-current operating lease liabilities Operating lease liability, non-current 26.5 28.1 Total operating lease liabilities: $ 33.1 $ 34.9 Financing lease liabilities: Current financing lease liabilities Accrued expenses and other current liabilities $ 0.1 $ 0.1 Non-current financing lease liabilities Deferred income taxes and other long-term liabilities 0.1 0.1 Total financing lease liabilities: $ 0.2 $ 0.2 The depreciable lives are limited by the expected lease term for operating lease assets and by shorter of either the expected lease term or economic useful life for financing lease assets. The Company’s leases generally do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring the lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment. The Company used incremental borrowing rates as of July 1, 2021 for leases that commenced prior to that date. The Company’s weighted average remaining lease term and weighted average discount rate for operating leases as of March 31, 2024 and December 31, 2023, respectively, are: March 31, 2024 December 31, 2023 Operating leases Weighted average remaining lease term (in years) 6.5 6.6 Weighted average discount rate 4.32 % 4.32 % The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under non-cancelable operating leases with terms of more than one year to the total lease liabilities recognized in the unaudited Condensed Consolidated Balance Sheets as of March 31, 2024 (in millions): Fiscal year ending December 31: 2024 $ 5.9 2025 6.9 2026 5.9 2027 5.1 2028 3.9 2029 and thereafter 10.2 Total undiscounted future minimum lease payments 37.9 Less: Imputed interest (4.8) Total operating lease liabilities $ 33.1 For the three months ended March 31, 2024 and three months ended March 31, 2023, operating lease costs (as defined under ASU 2016-02) were $2.7 million. Operating lease costs are included within costs of goods sold, selling, general and administrative, and research and development expenses on the consolidated statements of income and comprehensive income. Short-term lease costs, variable lease costs and sublease income were not material for the periods presented.
Leased Assets	Leased Assets The Company primarily leases certain logistics, office, and manufacturing facilities, as well as vehicles, copiers and other equipment. These operating leases generally have remaining lease terms between 1 month and 30 years, and some include options to extend (generally 1 to 10 years). The exercise of lease renewal options is at the Company’s discretion. The Company evaluates renewal options at lease inception and on an ongoing basis, and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. Lease agreements generally do not require material variable lease payments, residual value guarantees or restrictive covenants. The table below presents the locations of the operating lease assets and liabilities in the unaudited Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023, respectively (in millions): Balance Sheet Line Item March 31, 2024 December 31, 2023 Operating lease assets Operating lease right-of-use assets $ 31.1 $ 32.8 Financing lease assets Other assets $ 0.1 $ 0.1 Operating lease liabilities: Current operating lease liabilities Current operating lease liabilities $ 6.6 $ 6.8 Non-current operating lease liabilities Operating lease liability, non-current 26.5 28.1 Total operating lease liabilities: $ 33.1 $ 34.9 Financing lease liabilities: Current financing lease liabilities Accrued expenses and other current liabilities $ 0.1 $ 0.1 Non-current financing lease liabilities Deferred income taxes and other long-term liabilities 0.1 0.1 Total financing lease liabilities: $ 0.2 $ 0.2 The depreciable lives are limited by the expected lease term for operating lease assets and by shorter of either the expected lease term or economic useful life for financing lease assets. The Company’s leases generally do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring the lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment. The Company used incremental borrowing rates as of July 1, 2021 for leases that commenced prior to that date. The Company’s weighted average remaining lease term and weighted average discount rate for operating leases as of March 31, 2024 and December 31, 2023, respectively, are: March 31, 2024 December 31, 2023 Operating leases Weighted average remaining lease term (in years) 6.5 6.6 Weighted average discount rate 4.32 % 4.32 % The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under non-cancelable operating leases with terms of more than one year to the total lease liabilities recognized in the unaudited Condensed Consolidated Balance Sheets as of March 31, 2024 (in millions): Fiscal year ending December 31: 2024 $ 5.9 2025 6.9 2026 5.9 2027 5.1 2028 3.9 2029 and thereafter 10.2 Total undiscounted future minimum lease payments 37.9 Less: Imputed interest (4.8) Total operating lease liabilities $ 33.1 For the three months ended March 31, 2024 and three months ended March 31, 2023, operating lease costs (as defined under ASU 2016-02) were $2.7 million. Operating lease costs are included within costs of goods sold, selling, general and administrative, and research and development expenses on the consolidated statements of income and comprehensive income. Short-term lease costs, variable lease costs and sublease income were not material for the periods presented. Cash paid for amounts included in the measurement of operating lease liabilities was $2.1 million and $2.6 million for the three months ended March 31, 2024 and March 31, 2023, respectively, and these amounts are included in operating activities in the unaudited Condensed Consolidated Statements of Cash Flows. Operating lease assets obtained in exchange for new operating lease liabilities were zero and $0.2 million for the three months ended March 31, 2024 and March 31, 2023, respectively.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Unconditional Purchase Obligations The Company has entered into certain long-term unconditional purchase obligations with suppliers. These agreements are non-cancellable and specify terms, including fixed or minimum quantities to be purchased, fixed or variable price provisions, and the approximate timing of payment. As of March 31, 2024, unconditional purchase obligations were as follows (in millions): Fiscal year ending December 31: 2024 $ 45.6 2025 9.5 2026 1.1 2027 0.6 2028 and thereafter — Total $ 56.8 Litigation The Company is subject to various legal proceedings, claims, litigation, investigations and contingencies arising out of the ordinary course of business. While the ultimate results of such suits or other proceedings against the Company cannot be predicted with certainty, we believe the resolution of these matters will not have a material effect on our results of operations, financial condition, or cash flows. If we believe the likelihood of an adverse legal outcome is probable and the amount is reasonably estimable, we accrue a liability in accordance with accounting guidance for contingencies. We consult with legal counsel on matters related to litigation and seek input both within and outside the Company. In April 2023, one of our Russian customers made a claim against the Company, including liquidated damages for certain delays under the terms of an active project, in the amount of $19.3 million, and sent an updated claim statement in October 2023 totaling $21 million ($18 million of which accrue daily penalties), subject to a $14 million contractual cap (all amounts converted from Euros to U.S. Dollars). I n June 2023, the same customer made a demand against the Company for the return of all payments received by the Company ($10.2 million) related to a Finland nuclear power plant project cancelled in May 2022. No legal actions have been taken to date by the customer on any of these matters, and management disputes these claims, believes that the Company has substantial defenses and expects to vigorously defend against these claims. However, uncertainty exists as to the resolutions of these matters, including any impact from potential modifications of the underlying active contract and/or settlement of claims for the cancelled Finland project. As previously disclosed in our 2023 annual report, a lawsuit was filed against the Company in the fourth quarter of 2023 by a vendor alleging copyright infringement and breach of contract involving use of certain software licenses. On March 30, 2024 a settlement agreement was reached with the counterparty with no material impact to our March 31, 2024 financial statements.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The effective income tax rate was (4.7)% for the three months ended March 31, 2024, and 2.5% for the three months ended March 31, 2023. The difference in effective tax rate between the periods was primarily attributable to mix of earnings and the impact of valuation allowances. The effective income tax rate differs from the U.S. statutory rate of 21% due primarily to U.S. federal permanent differences and the impact of valuation allowances.

Supplemental Disclosures to Con

Supplemental Disclosures to Condensed Consolidated Statements of Cash Flows	3 Months Ended
	Mar. 31, 2024
Supplemental Cash Flow Elements [Abstract]
Supplemental Disclosures to Condensed Consolidated Statements of Cash Flows	Supplemental Disclosures to Condensed Consolidated Statements of Cash Flows Supplemental cash flow information and schedules of non-cash investing and financing activities (in millions): Three Months Ended March 31, Three Months Ended March 31, 2024 2023 Cash Paid For: Cash paid for interest $ 14.8 $ 13.9 Cash paid for income taxes $ 2.8 $ 2.8 Non-Cash Investing and Financing Activities: Property, plant, and equipment purchases in accrued expense and other liabilities $ 1.9 $ 0.2 Property, plant, and equipment purchases in accounts payable $ 1.3 $ 1.6 The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the unaudited Condensed Consolidated Balances Sheets that sum to the total of the same such amounts shown in the unaudited Condensed Consolidated Statements of Cash Flows (in millions). March 31, December 31, 2024 2023 Cash and cash equivalents $ 120.2 $ 128.8 Restricted cash—current 0.4 0.6 Restricted cash—non-current 1.1 1.1 Total cash, cash equivalents, and restricted cash $ 121.7 $ 130.5 Amounts included in restricted cash represent funds with various financial institutions to support performance bonds with irrevocable letters of credit for contractual obligations to certain customers.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation is awarded to employees and directors of the Company and accounted for in accordance with ASC 718, "Compensation—Stock Compensation". Stock-based compensation expense is recognized for equity awards over the vesting period based on their grant-date fair value. Stock-based compensation expense is included within the same financial statement caption where the recipient’s other compensation is reported. The Company accounts for forfeitures as they occur. The Company uses various forms of long-term incentives including, but not limited to restricted stock units ("RSUs") and performance-based restricted units ("PSUs"), provided that the granting of such equity awards is in accordance with the Company's 2021 Omnibus Incentive Plan (the "2021 Plan") as filed on Form S-8 with the SEC on December 27, 2021. 2021 Omnibus Incentive Plan We adopted and obtained stockholder approval at the special meeting of the stockholders on October 19, 2021 of the 2021 Plan. We initially reserved 19,952,329 shares of our Class A common stock for issuance pursuant to awards under the 2021 Plan. The total number of shares of our Class A common stock available for issuance under the 2021 Plan will be increased on the first day of each fiscal year following the date on which the 2021 Plan was adopted in an amount equal to the least of (i) three percent (3%) of the outstanding shares of Class A common stock on the last day of the immediately preceding fiscal year, (ii) 9,976,164 shares of Class A common stock and (iii) such number of shares of Class A common stock as determined by the Committee (as defined and designated under the 2021 Plan) in its discretion. Pursuant to these automatic increase provisions, the number of shares of our Class A common stock reserved for issuance pursuant to awards under the 2021 Plan increased to 38,492,328 shares at January 1, 2024. Any employee, director or consultant of the Company or any of its subsidiaries or affiliates is eligible to receive an award under the 2021 Plan, to the extent that an offer of such award is permitted by applicable law, stock market or exchange rules, and regulations or accounting or tax rules and regulations. The 2021 Plan provides for the grant of stock options (including incentive stock options and non-qualified stock options), stock appreciation rights, restricted stock, RSUs, PSUs, other stock-based awards, or any combination thereof. Each award will be set forth in a separate grant notice or agreement and will indicate the type and terms and conditions of the award. The purpose of the 2021 Plan is to motivate and reward employees and other individuals to perform at their highest level and contribute significantly to the success of the Company. During the three months ended March 31, 2024, the Company granted 548,939 RSUs and 453,560 PSUs to certain employees. The RSUs granted to employees are subject to service vesting conditions such that all awards are fully vested after three (3) years with equal annual installments vesting on the anniversary of the grant date. The expense will be recognized on a straight-line basis over the related service period for each tranche of awards. The PSUs are subject to service, performance, and market vesting conditions and allow a maximum issuance of shares of our Class A common stock of up to 200% of the granted PSUs based on the Company meeting certain established thresholds. The recipient will generally forfeit all of the awards if the recipient is no longer providing services to the Company before the end of the performance measurement period on December 31, 2026. Fifty percent (50%) of the PSU awards shall vest based on performance condition determined by the Company's adjusted EBITDA as measured from January 1, 2026 to December 31, 2026 with interpolated achievement levels of (i) 0% if the adjusted EBITDA is less than $250.0 million, (ii) between 50% and 100% if the adjusted EBITDA is at least $250.0 million and up to $265.0 million and (iii) between 100% and 200% if the adjusted EBITDA is at least $265.0 million and up to $280.0 million. The remaining fifty percent (50%) of the PSU awards shall vest based on performance condition determined by the Company's cumulative Management adjusted free cash flow ("adjusted cash flow") as measured from January 1, 2024 to December 31, 2026 with interpolated achievement levels of (i) 0% if the adjusted cash flow is less than $525.0 million, (ii) between 50% and 100% if the adjusted cash flow is at least $525.0 million and up to $575.0 million and (iii) between 100% and 200% if the adjusted cash flow is at least $575.0 million and up to $625.0 million. The overall payout result per the performance conditions shall be adjusted based on a market condition modifier determined by the Company's relative total shareholder return (TSR) during the performance period of January 1, 2024 to December 31, 2026, measured as a comparative percentile to the Company’s peers in the Russell 2000 Industrials index with achievement levels of: (i) -10% if the TSR percentile is below the 30th percentile level, (ii) 0% if the TSR percentile is at least at the 30th percentile level and up to the 55th percentile level and (iii) 10% if the TSR percentile is at least at the 56th percentile level and up to the 80th percentile level (or above the 80th percentile level with 10% being the maximum). The total payout is capped at 200% of the granted PSUs. During the three months ended March 31, 2023, the Company granted 695,351 RSUs and 233,165 PSUs to certain members of the Company's employees. The RSUs are subject to service vesting conditions with one-third of each award vesting on the anniversary of the grant date such that all awards are fully vested after three (3) years. The expense will be recognized on a straight-line basis over the related service period for each tranche of awards. . The PSUs are subject to service and performance/market vesting conditions and allow a maximum issuance of shares of our Class A common stock of up to 200% of the granted PSUs based on the Company meeting certain established thresholds. The recipient will generally forfeit all of the awards if the recipient is no longer providing services to the Company before the end of the performance measurement period on December 31, 2025. Fifty percent (50%) of the PSU awards shall vest based on a market condition determined by the Company’s relative total shareholder return (TSR) during the performance period of January 1, 2023 to December 31, 2025, measured as a comparative percentile to the Company’s peers in the Russell 2000 Industrials index with interpolated achievement levels of: (i) 0% if the TSR percentile is below the 30th percentile level, (ii) between 50% and 100% if the TSR percentile is at least at the 30th percentile level and up to the 55th percentile level and (iii) between 100% and 200% if the TSR percentile is at least at the 56th percentile level and up to the 80th percentile level (or above the 80th percentile level with 200% being the maximum). The remaining fifty percent (50%) of the PSU awards shall vest based on performance condition determined by the Company’s organic revenue growth percentage as measured from January 1, 2025 to December 31, 2025 as compared with January 1, 2023 to December 31, 2023 with interpolated achievement levels of (i) 0% if the organic growth revenue percentage is less than 3.0%, (ii) between 50% and 100% if the organic revenue growth percentage is at least 3.0% and up to 5.0% and (iii) between 100% and 200% if the organic revenue growth percentage is at least 5.0% and up to 7.0% (or above 7.0% but with 200% being the maximum). During the three months ended March 31, 2024, $2.6 million of stock-based compensation expense was recorded, of which $0.2 million was related to non-employee directors. During the three months ended March 31, 2023, $1.6 million of stock-based compensation expense was recorded, of which $0.2 million, respectively was related to non-employee directors. In addition, during the three months ended March 31, 2024, certain members of the Company's Directors elected to receive their quarterly retainer fees in the form of shares of Class A common stock. As such, the Company recorded related stock-based compensation expense for $0.1 million in the same periods. During the three months ended March 31, 2023, the Company recorded related stock-based compensation expense for $0.1 million, for the director payments in lieu of cash. Profits Interests In conjunction with entering into the Business Combination Agreement, on June 17, 2021 the Sponsor issued 4,200,000 Profits Interests to Lawrence Kingsley, the current Chairman of the Board of Directors of the Company, 3,200,000 Profits Interests to Thomas Logan, the Chief Executive Officer of Mirion, and 700,000 Profits Interests to Brian Schopfer, the Chief Financial Officer of Mirion. The Profits Interests are intended to be treated as profits interests for U.S. income tax purposes, pursuant to which Messrs. Logan, Schopfer and Kingsley will have an indirect interest in the founder shares held by the Sponsor. The Profits Interests are subject to service vesting conditions and market vesting conditions. Fifty percent (50%) of the Profits Interests granted to each of Messrs. Logan and Schopfer service-vest on each of the second and third anniversaries of the Closing, and fifty percent (50%) of the Profits Interests granted to Mr. Kingsley service-vest on each of the first and second anniversaries of the Closing, subject in each case to the continuous service of the grantee on such date. The market vesting conditions require that the price per share of Mirion's Class A common stock must meet or exceed certain established thresholds for 20 out of 30 trading days before the fifth anniversary of the Closing Date. The expense will be recognized on a straight-line basis over the related service period for each tranche of awards. Of the Profits Interests, 3.2 million have a market vesting threshold price of $12 per share of Mirion Class A common stock, 2.0 million have a threshold price of $14 per share of Mirion Class A common stock, and 3.0 million have a threshold price of $16 per share of Mirion Class A common stock. During the three months ended March 31, 2024, $0.9 million of stock-based compensation expense was recorded and no new Profit Interests were issued. During the three months ended March 31, 2023, $4.0 million of stock-based compensation expense was recorded and no new Profit Interests were issued.

Related-Party Transactions

Related-Party Transactions	3 Months Ended
	Mar. 31, 2024
Related Party Transactions [Abstract]
Related-Party Transactions	Related-Party Transactions Founder Shares As of the closing of the Business Combination, the Sponsor owned 18,750,000 shares of Class B common stock the ("Founder Shares") which automatically converted into 18,750,000 shares of Class A common stock at the closing of the Business Combination. The Founder Shares, are subject to certain vesting and forfeiture conditions and transfer restrictions, including performance vesting conditions under which the price per share of Mirion's Class A common stock must meet or exceed certain established thresholds of $12, $14, or $16 per share for 20 out of 30 trading days before the fifth anniversary of the Closing Date of the Business Combination. The Founder Shares will be forfeited to the Company for no consideration if they fail to vest before October 20, 2026. Private Placement Warrants The Sponsor purchased an aggregate of 8,500,000 private placement warrants (the "Private Placement Warrants") at a price of $2.00 per whole warrant ($17.0 million in the aggregate) in a private placement (the “Private Placement”) that closed concurrently with the closing of GSAH's initial public offering (the "IPO"). Each Private Placement Warrant is exercisable for one whole share of Class A common stock at a price of $11.50 per share, subject to adjustment in certain circumstances, including upon the occurrence of certain reorganization events. The Private Placement Warrants are non-redeemable and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees. The Private Placement Warrants are accounted for as liabilities as they contain terms and features that do not qualify for equity classification under ASC 815. See Note 16, Fair Value Measurements , for the fair value of the Private Placement Warrants at March 31, 2024. Profits Interests In connection with the Business Combination Agreement, the Sponsor issued 8,100,000 Profits Interests to certain individuals affiliated with or expected to be affiliated with Mirion after the Business Combination. The holders of the Profits Interests will have an indirect interest in the Founder Shares held by the Sponsor. The Profits Interests are subject to service and performance vesting conditions, including the occurrence of the Closing, and do not fully vest until all of the applicable conditions are satisfied. In addition, the Profits Interests are subject to certain forfeiture conditions. See Note 13, Stock-Based Compensation, for further detail regarding the Profits Interests. Registration Rights The holders of the Founder Shares and Private Placement Warrants are entitled to registration rights to require the Company to register the resale of any the Founder Shares and the shares underlying the Private Placement Warrants upon exercise pursuant to the Amended and Restated Registration Rights Agreement dated October 20, 2021 (the "RRA"). These holders are also entitled to certain piggyback registration rights. The RRA also includes customary indemnification and confidentiality provisions. The Company will bear the expenses incurred in connection with the filing of any registration statements filed pursuant to the terms of the RRA, including those expenses incurred in connection with the shelf-registration statement on Form S-1 filed on October 27, 2021 and declared effective on November 2, 2021. Charterhouse Capital Partners LLP The Company had entered into agreements with its primary pre-Business Combination investor, Charterhouse Capital Partners LLP ("CCP"), which obligated the Company to pay certain expenses in support of any secondary market offerings of its remaining shares owned after the Business Combination. During the three months ended March 31, 2024 and March 31, 2023, no expenses and $0.6 million of expenses were recorded, respectively. As of July 2023, CCP no longer owns shares in the Company.

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
Segment Information	Segment Information During the three months ended June 30, 2023, the Company renamed its Industrial segment as "Technologies." The following table summarizes select operating results for each reportable segment (in millions). Three Months Ended March 31, Three Months Ended March 31, 2024 2023 Revenues Medical $ 66.8 $ 66.4 Technologies 125.8 115.7 Consolidated revenues $ 192.6 $ 182.1 Segment Income (Loss) from Operations Medical $ 1.4 $ 0.7 Technologies 12.6 5.5 Total segment income from operations 14.0 6.2 Corporate and other (18.9) (19.8) Consolidated loss from operations $ (4.9) $ (13.6) The Company’s assets by reportable segment were not included, as this information is not reviewed by, nor otherwise provided to, the chief operating decision maker to make operating decisions or allocate resources. The following details revenues by geographic region. Revenues generated from external customers are attributed to geographic regions through sales from site locations (i.e., point of origin) (in millions). Revenues Three Months Ended March 31, Three Months Ended March 31, 2024 2023 North America Medical $ 60.4 $ 60.7 Technologies 58.6 55.2 Total North America 119.0 115.9 Europe Medical 6.4 5.7 Technologies 61.4 53.1 Total Europe 67.8 58.8 Asia Pacific Medical — — Technologies 5.8 7.4 Total Asia Pacific 5.8 7.4 Total revenues $ 192.6 $ 182.1 The following details revenues by timing of recognition (in millions): Revenues Three Months Ended March 31, Three Months Ended March 31, 2024 2023 Point in time $ 126.9 $ 118.3 Over time 65.7 63.8 Total revenues $ 192.6 $ 182.1 The following details revenues by product category (in millions): Revenues Three Months Ended March 31, Three Months Ended March 31, 2024 2023 Medical segment: Medical $ 66.8 $ 66.4 Technologies segment: Reactor Safety and Control Systems 50.3 42.1 Radiological Search, Measurement, and Analysis Systems 75.5 73.6 Total revenues $ 192.6 $ 182.1

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company applies fair value accounting to all financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. The fair value of the Company’s cash and cash equivalents, restricted cash, accounts receivable, and other current assets and liabilities approximates their carrying amounts due to the relatively short maturity of these items. The fair value of third-party debt approximates the carrying value because the interest rates are variable and reflect market rates. Fair Value of Financial Instruments The Company categorizes assets and liabilities recorded at fair value in the unaudited Condensed Consolidated Balance Sheets based upon the level of judgment associated with inputs used to measure their fair value. It is not practicable due to cost and effort for the Company to estimate the fair value of notes issued to related parties primarily due to the nature of their terms relative to the entity’s capital structure. Assets and liabilities carried at fair value are valued and disclosed in one of the following three levels of the valuation hierarchy: Level 1 – Inputs are unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs are quoted prices in active markets for similar assets or liabilities or inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Inputs are unobservable and require significant management judgment or estimation. The following table summarizes the financial assets and liabilities of the Company that are measured at fair value on a recurring basis (in millions): Fair Value Measurements at March 31, 2024 Level 1 Level 2 Level 3 Assets Cash, cash equivalents, and restricted cash $ 121.7 $ — $ — Discretionary retirement plan $ 4.1 $ 1.0 $ — Accrued interest receivable on cross currency swaps $ — $ 0.1 $ — Interest rate swap (Note 17) $ — $ 0.9 $ — Liabilities Discretionary retirement plan $ 4.1 $ 1.0 $ — Public warrants $ 42.0 $ — $ — Private placement warrants $ — $ 19.0 $ — Cross-currency rate swaps (Note 17) $ — $ 17.1 $ — Fair Value Measurements at December 31, 2023 Level 1 Level 2 Level 3 Assets Cash, cash equivalents, and restricted cash $ 130.5 $ — $ — Discretionary retirement plan $ 4.0 $ 1.0 $ — Accrued interest receivable on cross currency swaps $ — $ 0.1 $ — Interest rate swap (Note 17) $ — $ 0.1 $ — Liabilities Discretionary retirement plan $ 4.0 $ 1.0 $ — Public warrants $ 38.1 $ — $ — Private placement warrants $ — $ 17.3 $ — Cross-currency rate swaps (Note 17) $ — $ 23.3 $ — As of March 31, 2024 and December 31, 2023, the fair value of Public Warrants issued in connection with GSAH's IPO have been measured based on the listed market price of such Public Warrants, a Level 1 measurement. As the transfer of Private Placement Warrants to anyone who is not a permitted transferee would result in the Private Placement Warrants having substantially the same terms as the Public Warrants, we determined that the fair value of each Private Placement Warrant is equivalent to that of each Public Warrant. The determination of the fair value of the warrant liability may be subject to change as more current information becomes available and accordingly the actual results could differ significantly. Derivative warrant liabilities are classified as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. For the three months ended March 31, 2024, the Company recognized an unrealized loss resulting from an increase in the fair value of the warrant liabilities of $5.7 million, which is presented in the unaudited Condensed Consolidated Statements of Operations as change in fair value of warrant liabilities.

Derivatives and Hedging

Derivatives and Hedging	3 Months Ended
	Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Hedging	Derivatives and Hedging The Company's policy requires derivatives to be used solely for managing risks and not for speculative purposes. As a result of the Company’s European operations, the Company is exposed to fluctuations in exchange rates between euro and USD. As such, the Company entered into cross-currency rate swaps to manage currency risks related to our investments in foreign operations. The Company is also subject to interest rate risk related to the Credit Facilities. The Company manages its risk to interest rate fluctuations through the use of derivative financial instruments. As such, the Company entered into an interest rate swap (notional amount of $75.0 million) to mitigate the risk of adverse changes in benchmark interest rates on the Company's future interest payments. All derivative instruments are carried at fair value in the unaudited Condensed Consolidated Balance Sheets. The following table presents the fair values of the Company’s derivative instruments that were designated and qualified as part of a hedging relationship (in millions): Fair Value (1) Derivatives Designated as Hedging Instruments Balance Sheet Location March 31, 2024 December 31, 2023 Assets: Accrued Interest Receivable on Cross-Currency Rate Swaps Prepaid expenses and other currents assets $ 0.1 $ 0.1 Interest Rate Swap Other non-current assets 0.9 0.1 Total assets $ 1.0 $ 0.2 Liabilities: Cross-Currency Rate Swaps Accrued expenses and other current liabilities $ 7.7 $ 10.7 Cross-Currency Rate Swaps Other non-current liabilities $ 9.5 $ 12.6 Total liabilities $ 17.2 $ 23.3 (1) Refer to Note 16, Fair Value Measurements , for additional information related to the estimated fair value. Counterparty Credit Risk Outstanding financial derivative instruments expose the Company to credit loss in the event of nonperformance by the counterparties to the derivative agreements. The Company's credit exposure related to these financial instruments is represented by the notional amount of the hedging instruments. The Company manages its exposure to counterparty credit risk through minimum credit standards, diversification of counterparties, and procedures to monitor concentrations of credit risk. The Company's derivative instruments are with financial institutions of investment grade or better. Counterparty credit risk will be monitored through periodic review of counterparty bank’s credit ratings and public financial filings. Based on these factors, the Company considers the risk of counterparty default to be minimal. Cash Flow Hedging Strategy The Company uses cash flow hedges to minimize the variability in cash flows of assets or liabilities or forecasted transactions caused by fluctuations in interest rates. The changes in the fair values of derivatives designated as cash flow hedges are recorded in accumulated other comprehensive loss (“AOCL”) and are reclassified into the line item in the unaudited Condensed Consolidated Statements of Operations in which the hedged items are recorded in the same period the hedged items affect earnings. The changes in the fair values of hedges that are determined to be ineffective are immediately reclassified from AOCL into earnings. The maximum length of time for which the Company hedges its exposure to the variability in future cash flows is three years. The interest rate swap was entered into by the Company during the third quarter of 2023. During the three months ended March 31, 2024, the interest rate swap resulted in gains of $0.8 million recognized in other comprehensive income ("OCI"). Gains of $0.3 million in income through interest expense and reclassified from OCI during the same period. The cash inflows and outflows associated with the Company’s derivative contracts designated as cash flow hedges are classified as financing activities in the unaudited Condensed Consolidated Statements of Cash Flows. In addition, the Company did not have any ineffectiveness related to the interest rate swap during the three months ended March 31, 2024. Hedges of Net Investments in Foreign Operations Strategy The Company uses fixed-to-fixed cross-currency rate swaps ("CCRS") to protect the net investment on pre-tax basis in the Company’s EUR-denominated operations against changes in spot exchange rates. For derivative financial instruments that are designated and qualify as hedges of net investments in foreign operations, the changes in the fair values of the derivative financial instruments are recognized in net investment hedges adjustments, a component of AOCL, to offset the changes in the values of the net investments being hedged. Any ineffective portions of net investment hedges are reclassified from AOCL into earnings during the period of change. The following table summarizes the notional values and pretax impact of changes in the fair values of instruments designated as net investment hedges (in millions): Notional Amount Gain (Loss) Recognized in AOCL As of Three Months Ended March 31, 2024 Three Months Ended March 31, 2023 March 31, 2024 December 31, 2023 Cross-currency rate swaps € 238.8 € 238.8 $ 6.2 $ (2.9) Total € 238.8 € 238.8 $ 6.2 $ (2.9) The Company did not reclassify any gains or losses related to net investment hedges from AOCL into earnings during the three months ended March 31, 2024 and March 31, 2023, respectively. In addition, the Company did not have any ineffectiveness related to net investment hedges during the three months ended March 31, 2024 and 2023. The cash inflows and outflows associated with the Company’s derivative contracts designated as net investment hedges are classified as investing activities in the unaudited Condensed Consolidated Statements of Cash Flows.

Loss Per Share

Loss Per Share	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Loss Per Share	Loss Per Share A reconciliation of the numerator and denominator used in the calculation of basic and diluted loss per common share is as follows (in millions, except per share amounts): Three Months Ended March 31, Three Months Ended March 31, 2024 2023 Net loss attributable to Mirion Technologies, Inc. shareholders $ (25.8) $ (41.9) Weighted average common shares outstanding – basic and diluted 199.729 187.701 Net loss per common share attributable to Mirion Technologies, Inc. — basic and diluted $ (0.13) $ (0.22) Net loss per share of common stock is computed using the two-class method required for multiple classes of common stock and participating securities based upon their respective rights to receive dividends as if all income for the period has been distributed. Basic loss per share is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding, adjusted for the outstanding non-vested shares. Diluted loss per share is computed by giving effect to all potentially dilutive securities outstanding for the period using the treasury stock method or the if-converted method based on the nature of such securities. For periods in which the Company reports net losses, diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, because potentially dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company incurred a net loss for the three months ended March 31, 2024 and 2023, respectively; therefore, none of the potentially dilutive common shares were included in the diluted share calculations for those periods as they would have been anti-dilutive. The weighted average number of potentially dilutive common shares related to employee stock-based awards excluded as anti-dilutive for the three months ended March 31, 2024 and 2023 were 2.577 million and 0.687 million, respectively. Upon the closing of the Business Combination, the following classes of common stock were considered in the loss per share calculation. Class A Common Stock Holders of shares of our Class A common stock are entitled to one vote for each share held of record on all matters on which stockholders are entitled to vote generally, including the election or removal of directors. The holders of our Class A common stock do not have cumulative voting rights in the election of directors. Holders of shares of our Class A common stock are entitled to receive dividends when and if declared by the Company's Board of Directors out of funds legally available therefor, subject to any statutory or contractual restrictions on the payment of dividends and to any restrictions on the payment of dividends imposed by the terms of any outstanding preferred stock. Upon our liquidation, dissolution or winding up and after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, the holders of shares of our Class A common stock will be entitled to receive pro rata our remaining assets available for distribution. Class A common stock issued and outstanding is included in the Company’s basic loss per share calculation, with the exception of Founder Shares discussed below. Class B Common Stock Holders of shares of our Class B common stock are entitled to one vote for each share held of record on all matters on which stockholders are entitled to vote generally, including the election or removal of directors. If at any time the ratio at which shares of IntermediateCo Class B common stock are redeemable or exchangeable for shares of our Class A common stock changes from one-for-one as the number of votes to which our Class B common stockholders are entitled will be adjusted accordingly. The holders of our Class B common stock do not have cumulative voting rights in the election of directors. Except for transfers to us or to certain permitted transferees set forth in the IntermediateCo certificate of incorporation, paired interests may not be sold, transferred or otherwise disposed of. Holders of shares of our Class B common stock are not entitled to economic interests in us or to receive dividends or to receive a distribution upon our liquidation or winding up. However, if IntermediateCo makes distributions to us other than solely with respect to our Class A common stock, the holders of paired interests will be entitled to receive distributions pro rata in accordance with the percentages of their respective shares of IntermediateCo Class B common stock. Our Class B common stock has voting rights but no economic interest in the Company and therefore are excluded from the calculation of basic and diluted earnings per share. Warrants As described above, the Company has outstanding warrants to purchase up to 27,249,779 shares of Class A common stock (including 18,749,779 Public Warrants and 8,500,000 Private Placement Warrants). One whole warrant entitles the holder thereof to purchase one share of Mirion Class A common stock at a price of $11.50 per share. The Company’s warrants are not included in the Company’s calculation of basic loss per share and are excluded from the calculation of diluted loss per share because their inclusion would be anti-dilutive. Founder Shares Founder shares are subject to certain vesting events and forfeit if a required vesting event does not occur within five years of the closing of the Business Combination. The founder shares are subject to vesting in three equal tranches, based on the volume-weighted average price of our Class A common stock being greater than or equal to $12.00, $14.00 and $16.00 per share for any 20 trading days in any 30 consecutive trading day period. Holders of the founder shares are entitled to vote such founder shares and receive dividends and other distributions with respect to such founder shares prior to vesting, but such dividends and other distributions with respect to unvested founder shares will be set aside by the Company and shall only be paid to the holders of the founder shares upon the vesting of such founder shares. As the holders of the founder shares are not entitled to participate in earnings unless the vesting conditions are met, the 18,750,000 founders shares have been excluded from the calculation of basic earnings per share. The founders shares are also excluded from the calculation of diluted earnings per share because their inclusion would be anti-dilutive. Stock-Based Awards

Restructuring

Restructuring	3 Months Ended
	Mar. 31, 2024
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring The Company incurs costs associated with restructuring initiatives intended to improve operating performance, profitability, and working capital levels. Actions associated with these initiatives may include improving productivity, workforce reductions, and the consolidation of facilities. As of March 31, 2024, the Company does not expect a significant impact of additional charges from restructuring actions in the next 12 months. The Company’s restructuring expenses are comprised of the following (in millions): Three Months Ended March 31, 2024 Cost of revenue Selling, general Total Severance and employee costs $ — $ — $ — Other (1) — — — Total $ — $ — $ — Three Months Ended March 31, 2023 Cost of revenue Selling, general Total Severance and employee costs $ — $ 1.2 $ 1.2 Other (1) — 0.2 0.2 Total $ — $ 1.4 $ 1.4 (1) Includes facilities, inventory write-downs, outside services, legal matters, and IT costs. The following table summarizes restructuring expenses for each reportable segment (in millions): Three Months Ended March 31, 2024 2023 Restructuring expenses: Medical $ — $ 0.3 Technologies — 0.1 Corporate and other — 1.0 Total $ — $ 1.4 No amounts were accrued for restructuring in Accrued expenses and other current liabilities in the accompanying unaudited Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023, respectively.

Noncontrolling Interests

Noncontrolling Interests	3 Months Ended
	Mar. 31, 2024
Noncontrolling Interest [Abstract]
Noncontrolling Interests	Noncontrolling Interests On October 20, 2021, Mirion Technologies, Inc. consummated its previously announced Business Combination pursuant to the Business Combination Agreement. Before the Closing of the Business Combination, the Sellers had the option to elect to have their equity consideration issued as either shares of Class A common stock or Paired Interests. The Sellers receiving shares of Class B common stock also received one share of IntermediateCo Class B common stock per share of Class B common stock as a Paired Interest. Each of the shares of Class A common stock and each Paired Interest were valued at $10.00 per share for purposes of determining the aggregate number of shares issued to the Sellers. Holders of shares of our Class B common stock are entitled to one vote for each share held of record on all matters on which stockholders are entitled to vote generally, including the election or removal of directors. If at any time the ratio at which shares of IntermediateCo Class B common stock are redeemable or exchangeable for shares of the Company’s our Class A common stock changes from one-for-one, as the number of votes to which our Class B common stockholders are entitled will be adjusted accordingly. The holders of our the Company’s Class B common stock do not have cumulative voting rights in the election of directors. Except for transfers to us or to certain permitted transferees set forth in the IntermediateCo certificate of incorporation, paired interests may not be sold, transferred or otherwise disposed of. The holders of IntermediateCo Class B common stock have the right to require IntermediateCo to redeem all or a portion of their IntermediateCo Class B common stock for, at the Company’s election, (1) newly issued shares of the Company’s Class A common stock on a one-for-one basis or (2) a cash payment equal to the product of the number of shares of IntermediateCo Class B common stock subject to redemption and the arithmetic average of the closing stock prices for a share of the Company’s Class A common stock for each of three (3) consecutive full trading days ending on and including the last full trading day immediately prior to the date of redemption (subject to customary adjustments, including for stock splits, stock dividends and reclassifications). This redemption right became available upon the expiration of certain lockup restrictions on April 18, 2022. At the Closing Date, the Company owned 100% of the voting shares (Class A) of IntermediateCo and approximately 96% of the non-voting Class B shares of IntermediateCo. The Company recognized noncontrolling interests for the 8,560,540 shares, representing approximately 4% of the non-voting Class B shares, of IntermediateCo that are not attributable to the Company. After the conversion in the current quarter, the Company recognized noncontrolling interests for the 7,326,423 shares, representing the 3.2% of the non-voting Class B shares of IntermediateCo, that are not attributable to the Company. As of March 31, 2024, noncontrolling interests of $60.7 million were reflected in the unaudited Condensed Consolidated Statements of Stockholders’ Equity.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss The components of accumulated other comprehensive loss, net of tax, consist of the following (in millions): March 31, 2024 December 31, 2023 Cumulative foreign currency translation adjustment, net of tax $ (67.0) $ (52.4) Unrealized gain on pension and postretirement benefit plans, net of tax 2.0 2.0 Unrealized loss on net investment hedges, net of tax (13.1) (17.9) Unrealized gain on cash flow hedges, net of tax 0.7 0.1 Less: cumulative loss attributable to noncontrolling interests (3.2) (2.9) Accumulated other comprehensive loss $ (74.2) $ (65.3)

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On April 18, 2024, Mirion announced a redemption of all Public Warrants. Public Warrant holders may continue to exercise their Public Warrants until immediately before 5:00 p.m. New York City time on May 20, 2024 (the "Redemption Date") and receive shares of Class A Common Stock (i) in exchange for a $11.50 cash payment per warrant, or (ii) on a “cashless” basis, in which case the exercising holder will receive 0.220 of a share of Class A Common Stock for each Public Warrant (rounded down to the nearest whole number of shares across all warrants exercised at one time). Public Warrants not exercised by 5:00 p.m. New York City time on the Redemption Date will be redeemed for $0.10 per Public Warrant.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net loss attributable to Mirion Technologies, Inc. shareholders	$ (25.8)	$ (41.9)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	During the three months ended March 31, 2024, no director or officer (as defined in Rule 16a-1(f) of the Exchange Act) of the Company adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement" as each term is defined in Item 408(a) of Regulation S-K, except as set forth below: Name and Title Action Applicable Duration of Trading Arrangement Rule 10b5-1 Trading Arrangement? (Y/N) (1) Aggregate Number of Securities Subject to Trading Arrangement Thomas D. Logan Chief Executive Officer Adopt February 27, 2024 May 25, 2024 - April 30, 2025 Y 90,000 (2) Brian Schopfer Chief Financial Officer Adopt February 26, 2024 June 11, 2024 - June 11, 2025 Y 182,195 (3) Emmanuelle Lee Chief Legal Officer, Chief Compliance Officer and Corporate Secretary Adopt March 7, 2024 June 6, 2024 - February 28, 2025 Y 50,000 (4) (1) Denotes whether the trading plan is intended, when adopted, to satisfy the affirmative defense of Rule 10b5-1(c). (2) Reflects shares of Class B common stock of the Company held of record by Aere Perennius, LLC., a limited liability company established for the benefit of Mr. Logan's adult children, to be sold in twelve (12) monthly installments of 7,500 shares each for the duration of the trading arrangement, subject to a limit price. The shares of Class B common stock will be exchanged for shares of Class A common stock of the Company if sales are triggered under the trading arrangement. (3) Reflects shares of Class B common stock of the Company held of record by Mr. Schopfer to be sold in two (2) installments of up to 95,238 and 86,957 shares each for the duration of the trading arrangement, subject to two different limit prices. The shares of Class B common stock will be exchanged for shares of Class A common stock of the Company if sales are triggered under the trading arrangement. Mr. Schopfer intends to terminate this Rule 10b5-1 trading plan when the Company trading window opens during the second quarter of 2024. (4) Reflects shares of Class B common stock of the Company held of record by the Lee Revocable Living Trust for the benefit of Ms. Lee, her spouse and beneficiaries to be sold in ten (10) monthly installments of 5,000 shares each for the duration of the trading arrangement, subject to a limit price. The shares of Class B common stock will be exchanged for shares of Class A common stock of the Company if sales are triggered under the trading arrangement.
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Thomas D. Logan [Member]
Trading Arrangements, by Individual
Name	Thomas D. Logan
Title	Chief Executive Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	February 27, 2024
Arrangement Duration	340 days
Aggregate Available	90,000
Brian Schopfer [Member]
Trading Arrangements, by Individual
Name	Brian Schopfer
Title	Chief Financial Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	February 26, 2024
Arrangement Duration	365 days
Aggregate Available	182,195
Emmanuelle Lee [Member]
Trading Arrangements, by Individual
Name	Emmanuelle Lee
Title	Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	March 7, 2024
Arrangement Duration	267 days
Aggregate Available	50,000

Nature of Business and Summar_2

Nature of Business and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Nature of Business	Nature of Business Mirion Technologies, Inc. (“Mirion,” the “Company," "we," "our," or "us" and formerly GS Acquisition Holdings Corp II ("GSAH")) is a global provider of radiation detection, measurement, analysis, and monitoring products and services to the medical, nuclear, and defense end markets. On October 20, 2021, Mirion Technologies, Inc. was formed (formerly known as GS Acquisition Holdings Corp II or "GSAH") when it consummated its business combination with GSAH (the "Business Combination") pursuant to the Business Combination Agreement dated June 17, 2021. We provide products and services through our two operating and reportable segments; (i) Medical and (ii) Technologies. The Medical segment provides radiation oncology quality assurance, delivering patient safety solutions for diagnostic imaging and radiation therapy centers around the world, dosimetry solutions for monitoring the total amount of radiation medical staff members are exposed to over time, radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy, and radionuclide therapy products for nuclear medicine applications such as shielding, product handling, medical imaging furniture, and rehabilitation products. The Technologies segment provides robust, field ready personal radiation detection and identification equipment for defense applications and radiation detection and analysis tools for power plants, labs, and research applications. Nuclear power plant product offerings are used for the full nuclear power plant lifecycle including core detectors and essential measurement devices for new build, maintenance, decontamination and decommission equipment for monitoring and control during fuel dismantling and remote environmental monitoring.
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited Condensed Consolidated Financial Statements and Notes to Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for financial statements and pursuant to the accounting and disclosure rules and regulations of the U.S. Securities and Exchange Commission (the "SEC") for interim financial information. The interim unaudited Condensed Consolidated Financial Statements reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair representation of the results for the periods presented and should be read in conjunction with the audited Consolidated Financial Statements and notes thereto for the period ended December 31, 2023, which include a complete set of footnote disclosures, including our significant accounting policies included in our Annual Report on Form 10-K. The results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned and majority-owned or controlled subsidiaries. For consolidated subsidiaries where our ownership is less than 100%, the portion of the net income or loss allocated to noncontrolling interests is reported as “Income (Loss) attributable to noncontrolling interests” in the unaudited Condensed Consolidated Statements of Operations. All intercompany accounts and transactions have been eliminated in consolidation.
Segments	Segments
Use of Estimates	Use of Estimates
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets
Facility and Equipment Decommissioning Liabilities	Facility and Equipment Decommissioning Liabilities
Revenue Recognition	Revenue Recognition The Company recognizes revenue from arrangements that include performance obligations to design, engineer, manufacture, deliver, and install products. If a performance obligation does not qualify for over-time revenue recognition, revenue is then recognized at the point-in-time in which control of the distinct good or service is transferred to the customer, typically based upon the terms of delivery. Revenue derived from passive dosimetry and analytical services is of a subscription nature and is provided to customers on an agreed-upon recurring monthly, quarterly or annual basis. Revenue is recognized ratably over the service period as the service is continuous, and no other discernible pattern of recognition is evident. Contract Balances The timing of the Company's revenue recognition, invoicing, and cash collections results in accounts receivable, costs and estimated earnings in excess of billings on uncompleted contracts, and deferred contract revenue. Refer to Note 4, Contracts in Progress for further details. Remaining Performance Obligations
Warrant Liability	Warrant Liability As of March 31, 2024, the Company had outstanding warrants to purchase up to 27,249,779 shares of Class A common stock. Th
Treasury Stock	Treasury Stock We account for treasury stock under the cost method pursuant to the provisions of ASC 505-30, Treasury Stock. Under the cost method, the gross cost of the shares reacquired is charged to a contra equity account, treasury stock. The equity accounts that were originally credited for the original share issuance, Common Stock and additional paid-in capital, remain intact. If the treasury shares are ever reissued in the future at a price higher than its cost, the difference is recorded as a component of additional paid-in-capital in the unaudited Condensed Consolidated Balance Sheets. When treasury stock is re-issued at a price lower than its cost, the difference is recorded as a component of additional paid-in-capital to the extent that there are previously recorded gains to offset the losses. If there are no treasury stock gains in additional paid-in-capital, the losses upon re-issuance of treasury stock are recorded as a reduction of retained earnings in the unaudited Condensed Consolidated Balance Sheets. If treasury stock is reissued in the future, a cost flow assumption (e.g., FIFO, LIFO or specific identification) will be adopted to compute excesses and deficiencies upon subsequent share reissuance.
Concentrations of Risk	Concentrations of Risk Financial instruments that are potentially subject to concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company maintains cash in bank deposit accounts that, at times, may exceed the insured limits of the local country. The Company has not experienced any losses in such accounts.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Accounting Guidance Issued But Not Yet Adopted In October 2023, the FASB issued ASU 2023-06 “Disclosure Improvements”. ASU 2023-06 clarifies or improves disclosure and presentation requirements of a variety of topics. For entities subject to the SEC’s existing disclosure requirements, the effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. For all entities, if by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the codification and will not become effective for any entity. The Company is currently evaluating the impact of this ASU. In November 2023, the FASB issued ASU 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures". ASU 2023-07 improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. For all entities, the amendments will be effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments will be applied retrospectively to all prior periods presented in the financial statements. The Company is evaluating the impact of this new standard and believes that the adoption will result in additional disclosures, but will not have any other impact on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". ASU 2023-09 enhances the existing income tax disclosures primarily related to the rate reconciliation and income taxes paid information. For public business entities, the amendments are effective for annual periods beginning after December 15, 2024, with early adoption permitted for annual financial statements that have not yet been issued or made available for issuance. The amendments will be applied on a prospective basis, with retrospective application permitted. The Company is currently evaluating the impact of this ASU. In March 2024, the FASB issued ASU 2024-01 "Compensation - Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards". ASU 2024-01 improves GAAP by demonstrating how an entity should apply the scope guidance to determine whether profits interest and similar awards should be accounted for in accordance with Topic 718. For public business entities, the amendments are effective for annual periods beginning after December 15, 2024, and interim periods within those annual periods. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The amendments should be applied either (1) retrospectively to all prior periods presented in the financial statements or (2) prospectively to profits interest and similar awards granted or modified on or after the date at which the entity first applies the amendments. The Company is currently evaluating the impact of this ASU. Other Guidance Issued But Not Yet Adopted In March 2024, the SEC issued its final climate disclosure rules, which require the disclosure of climate-related information in annual reports and registration statements. The rules require disclosure in the audited financial statements of certain effects of severe weather events and other natural conditions above certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates, if material. Disclosure requirements will begin phasing in for fiscal years beginning on or after January 1, 2025. On April 4, 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. We are currently evaluating the impact of the new rules and considering the potential outcome of the legal challenges.

Nature of Business and Summar_3

Nature of Business and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Schedule of Other Current Assets	The components of prepaid expenses and other current assets consist of the following (in millions): March 31, 2024 December 31, 2023 Prepaid insurance $ 2.3 $ 1.0 Prepaid vendor deposits 7.3 7.6 Prepaid software licenses 3.9 3.5 Short-term marketable securities 5.4 5.3 Income tax receivable and prepaid income taxes 1.0 8.0 Other tax receivables 1.4 1.4 Other current assets 17.2 17.3 $ 38.5 $ 44.1

Contracts in Progress (Tables)

Contracts in Progress (Tables)	3 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Cost and Billings on Uncompleted Construction Type Long Term Contracts or Programs	Costs and billings on uncompleted construction-type contracts consist of the following (in millions): March 31, 2024 December 31, 2023 Costs incurred on contracts (from inception to completion) $ 353.1 $ 324.5 Estimated earnings 211.8 208.7 Contracts in progress 564.9 533.2 Less: billings to date (524.3) (511.3) $ 40.6 $ 21.9
Contract with Customer, Contract Asset, Contract Liability, and Receivable	The carrying amounts related to uncompleted construction-type contracts are included in the accompanying unaudited Condensed Consolidated Balance Sheets under the following captions (in millions): March 31, 2024 December 31, 2023 Costs and estimated earnings in excess of billings on uncompleted contracts – current $ 62.6 $ 48.7 Costs and estimated earnings in excess of billings on uncompleted contracts – non-current (1) 11.3 18.2 Billings in excess of costs and estimated earnings on uncompleted contracts – current (2) (31.5) (41.1) Billings in excess of costs and estimated earnings on uncompleted contracts – non-current (3) (1.8) (3.9) $ 40.6 $ 21.9 (1) Included in other assets within the Condensed Consolidated Balance Sheets. (2) Included in deferred contract revenue – current within the Condensed Consolidated Balance Sheets. (3)

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2024
Inventory Disclosure [Abstract]
Schedule of Inventory	The components of inventories consist of the following (in millions): March 31, 2024 December 31, 2023 Raw materials $ 66.5 $ 67.2 Work in progress 36.7 35.3 Finished goods 43.6 41.6 $ 146.8 $ 144.1

Property, Plant, and Equipmen_2

Property, Plant, and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment, net consist of the following (in millions): Depreciable March 31, 2024 December 31, 2023 Land, buildings, and leasehold improvements 3-39 years $ 49.9 $ 49.4 Machinery and equipment 5-15 years 39.6 38.5 Badges 3-5 years 44.2 41.0 Furniture, fixtures, computer equipment and other 3-10 years 22.9 22.9 Software development costs 3-5 years 11.0 10.7 Construction in progress (1) — 32.5 28.6 200.1 191.1 Less: accumulated depreciation and amortization (61.8) (56.6) $ 138.3 $ 134.5 (1) Includes $5.6 million and $4.2 million of Construction in progress for internally developed software as of March 31, 2024, and December 31, 2023, respectively.
Schedule of Depreciation Expense	Total depreciation expense included in costs of revenues and operating expenses was as follows (in millions): Three Months Ended Three Months Ended March 31, 2024 March 31, 2023 Depreciation expense in: Cost of revenues $ 5.3 $ 4.7 Operating expenses $ 2.0 $ 2.9

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Accrued Expenses and Other Current Liabilities [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following (in millions): March 31, 2024 December 31, 2023 Compensation and related benefit costs $ 34.7 $ 41.8 Customer deposits 8.0 8.5 Accrued commissions 0.3 0.3 Accrued warranty costs 4.9 4.5 Non-income taxes payable 9.2 11.8 Pension and other post-retirement obligations 0.3 0.3 Income taxes payable 2.7 4.2 Derivative liability 7.7 10.7 Other accrued expenses 11.2 13.5 Total $ 79.0 $ 95.6

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table shows changes in the carrying amount of goodwill by reportable segment as of March 31, 2024 and December 31, 2023 (in millions): Medical Technologies Consolidated Balance—December 31, 2023 $ 633.4 $ 814.2 $ 1,447.6 Measurement period adjustment 0.6 — 0.6 Translation adjustment — (8.0) (8.0) Balance—March 31, 2024 $ 634.0 $ 806.2 $ 1,440.2 Gross carrying amounts and cumulative goodwill impairment losses are as follows (in millions): March 31, 2024 December 31, 2023 Gross Carrying Amount Cumulative Impairment Gross Carrying Amount Cumulative Impairment Goodwill $ 1,652.0 $ (211.8) $ 1,659.4 $ (211.8)
Schedule of Finite-Lived Intangible Assets	A summary of intangible assets useful lives, gross carrying value and related accumulated amortization is below (in millions): March 31, 2024 Original Average Gross Carrying Accumulated Net Book Customer relationships 6 - 13 $ 339.2 $ (155.8) $ 183.4 Distributor relationships 7 - 13 60.9 (17.8) 43.1 Developed technology 5 - 16 262.3 (75.1) 187.2 Trade names 3 - 10 99.0 (24.4) 74.6 Backlog and other 1 - 4 75.2 (59.2) 16.0 Total $ 836.6 $ (332.3) $ 504.3 December 31, 2023 Original Average Gross Carrying Accumulated Net Book Customer relationships 6 - 13 $ 340.8 $ (143.1) $ 197.7 Distributor relationships 7 - 13 60.9 (16.0) 44.9 Developed technology 5 - 16 264.1 (67.8) 196.3 Trade names 3 - 10 99.7 (22.1) 77.6 Backlog and other 1 - 4 76.0 (53.7) 22.3 Total $ 841.5 $ (302.7) $ 538.8
Schedule of Finite-lived Intangible Assets Amortization Expense	Aggregate amortization expense for intangible assets included in cost of revenues and operating expenses was as follows (in millions): Three Months Ended March 31, Three Months Ended March 31, 2024 2023 Amortization expense for intangible assets in: Cost of revenues $ 6.8 $ 6.7 Operating expenses $ 24.7 $ 26.9

Borrowings (Tables)

Borrowings (Tables)	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Schedule of Third Party Notes Payable	Third-party debt consist of the following (in millions): March 31, 2024 December 31, 2023 2021 Credit Agreement $ 694.6 $ 694.6 Canadian Financial Institution 1.0 1.0 Other 1.7 2.8 Total third-party debt 697.3 698.4 Less: third-party debt, current (0.1) (1.2) Less: deferred financing costs (11.8) (12.5) Third-party debt, non-current $ 685.4 $ 684.7
Schedule of Contractual Principal Payments	At March 31, 2024, contractual principal payments of total third-party borrowings are as follows (in millions): Remainder of 2024 $ 0.1 Fiscal year ending December 31: 2025 0.1 2026 1.7 2027 0.1 2028 694.7 Thereafter 0.6 Gross Payments 697.3 Unamortized debt issuance costs (11.8) Total third-party borrowings, net of debt issuance costs $ 685.5

Leased Assets (Tables)

Leased Assets (Tables)	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Schedule of Operating Lease Assets and Liabilities on Balance Sheet	The table below presents the locations of the operating lease assets and liabilities in the unaudited Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023, respectively (in millions): Balance Sheet Line Item March 31, 2024 December 31, 2023 Operating lease assets Operating lease right-of-use assets $ 31.1 $ 32.8 Financing lease assets Other assets $ 0.1 $ 0.1 Operating lease liabilities: Current operating lease liabilities Current operating lease liabilities $ 6.6 $ 6.8 Non-current operating lease liabilities Operating lease liability, non-current 26.5 28.1 Total operating lease liabilities: $ 33.1 $ 34.9 Financing lease liabilities: Current financing lease liabilities Accrued expenses and other current liabilities $ 0.1 $ 0.1 Non-current financing lease liabilities Deferred income taxes and other long-term liabilities 0.1 0.1 Total financing lease liabilities: $ 0.2 $ 0.2
Schedule of Undiscounted Future Minimum Lease Payments	The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under non-cancelable operating leases with terms of more than one year to the total lease liabilities recognized in the unaudited Condensed Consolidated Balance Sheets as of March 31, 2024 (in millions): Fiscal year ending December 31: 2024 $ 5.9 2025 6.9 2026 5.9 2027 5.1 2028 3.9 2029 and thereafter 10.2 Total undiscounted future minimum lease payments 37.9 Less: Imputed interest (4.8) Total operating lease liabilities $ 33.1
Lease, Cost	The Company’s weighted average remaining lease term and weighted average discount rate for operating leases as of March 31, 2024 and December 31, 2023, respectively, are: March 31, 2024 December 31, 2023 Operating leases Weighted average remaining lease term (in years) 6.5 6.6 Weighted average discount rate 4.32 % 4.32 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Schedule of Unconditional Purchase Obligations	As of March 31, 2024, unconditional purchase obligations were as follows (in millions): Fiscal year ending December 31: 2024 $ 45.6 2025 9.5 2026 1.1 2027 0.6 2028 and thereafter — Total $ 56.8

Supplemental Disclosures to C_2

Supplemental Disclosures to Condensed Consolidated Statements of Cash Flows (Tables)	3 Months Ended
	Mar. 31, 2024
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow, Supplemental Disclosures	Supplemental cash flow information and schedules of non-cash investing and financing activities (in millions): Three Months Ended March 31, Three Months Ended March 31, 2024 2023 Cash Paid For: Cash paid for interest $ 14.8 $ 13.9 Cash paid for income taxes $ 2.8 $ 2.8 Non-Cash Investing and Financing Activities: Property, plant, and equipment purchases in accrued expense and other liabilities $ 1.9 $ 0.2 Property, plant, and equipment purchases in accounts payable $ 1.3 $ 1.6 The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the unaudited Condensed Consolidated Balances Sheets that sum to the total of the same such amounts shown in the unaudited Condensed Consolidated Statements of Cash Flows (in millions). March 31, December 31, 2024 2023 Cash and cash equivalents $ 120.2 $ 128.8 Restricted cash—current 0.4 0.6 Restricted cash—non-current 1.1 1.1 Total cash, cash equivalents, and restricted cash $ 121.7 $ 130.5

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The following table summarizes select operating results for each reportable segment (in millions). Three Months Ended March 31, Three Months Ended March 31, 2024 2023 Revenues Medical $ 66.8 $ 66.4 Technologies 125.8 115.7 Consolidated revenues $ 192.6 $ 182.1 Segment Income (Loss) from Operations Medical $ 1.4 $ 0.7 Technologies 12.6 5.5 Total segment income from operations 14.0 6.2 Corporate and other (18.9) (19.8) Consolidated loss from operations $ (4.9) $ (13.6)
Revenue from External Customers by Geographic Areas	The following details revenues by geographic region. Revenues generated from external customers are attributed to geographic regions through sales from site locations (i.e., point of origin) (in millions). Revenues Three Months Ended March 31, Three Months Ended March 31, 2024 2023 North America Medical $ 60.4 $ 60.7 Technologies 58.6 55.2 Total North America 119.0 115.9 Europe Medical 6.4 5.7 Technologies 61.4 53.1 Total Europe 67.8 58.8 Asia Pacific Medical — — Technologies 5.8 7.4 Total Asia Pacific 5.8 7.4 Total revenues $ 192.6 $ 182.1
Revenue from External Customers by Products and Services	The following details revenues by product category (in millions): Revenues Three Months Ended March 31, Three Months Ended March 31, 2024 2023 Medical segment: Medical $ 66.8 $ 66.4 Technologies segment: Reactor Safety and Control Systems 50.3 42.1 Radiological Search, Measurement, and Analysis Systems 75.5 73.6 Total revenues $ 192.6 $ 182.1
Disaggregation of Revenue	The following details revenues by timing of recognition (in millions): Revenues Three Months Ended March 31, Three Months Ended March 31, 2024 2023 Point in time $ 126.9 $ 118.3 Over time 65.7 63.8 Total revenues $ 192.6 $ 182.1

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Summary of Assets and Liabilities Measured at Fair Value	The following table summarizes the financial assets and liabilities of the Company that are measured at fair value on a recurring basis (in millions): Fair Value Measurements at March 31, 2024 Level 1 Level 2 Level 3 Assets Cash, cash equivalents, and restricted cash $ 121.7 $ — $ — Discretionary retirement plan $ 4.1 $ 1.0 $ — Accrued interest receivable on cross currency swaps $ — $ 0.1 $ — Interest rate swap (Note 17) $ — $ 0.9 $ — Liabilities Discretionary retirement plan $ 4.1 $ 1.0 $ — Public warrants $ 42.0 $ — $ — Private placement warrants $ — $ 19.0 $ — Cross-currency rate swaps (Note 17) $ — $ 17.1 $ — Fair Value Measurements at December 31, 2023 Level 1 Level 2 Level 3 Assets Cash, cash equivalents, and restricted cash $ 130.5 $ — $ — Discretionary retirement plan $ 4.0 $ 1.0 $ — Accrued interest receivable on cross currency swaps $ — $ 0.1 $ — Interest rate swap (Note 17) $ — $ 0.1 $ — Liabilities Discretionary retirement plan $ 4.0 $ 1.0 $ — Public warrants $ 38.1 $ — $ — Private placement warrants $ — $ 17.3 $ — Cross-currency rate swaps (Note 17) $ — $ 23.3 $ —

Derivatives and Hedging (Tables

Derivatives and Hedging (Tables)	3 Months Ended
	Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	The following table presents the fair values of the Company’s derivative instruments that were designated and qualified as part of a hedging relationship (in millions): Fair Value (1) Derivatives Designated as Hedging Instruments Balance Sheet Location March 31, 2024 December 31, 2023 Assets: Accrued Interest Receivable on Cross-Currency Rate Swaps Prepaid expenses and other currents assets $ 0.1 $ 0.1 Interest Rate Swap Other non-current assets 0.9 0.1 Total assets $ 1.0 $ 0.2 Liabilities: Cross-Currency Rate Swaps Accrued expenses and other current liabilities $ 7.7 $ 10.7 Cross-Currency Rate Swaps Other non-current liabilities $ 9.5 $ 12.6 Total liabilities $ 17.2 $ 23.3 (1) Refer to Note 16, Fair Value Measurements , for additional information related to the estimated fair value.
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)	The following table summarizes the notional values and pretax impact of changes in the fair values of instruments designated as net investment hedges (in millions): Notional Amount Gain (Loss) Recognized in AOCL As of Three Months Ended March 31, 2024 Three Months Ended March 31, 2023 March 31, 2024 December 31, 2023 Cross-currency rate swaps € 238.8 € 238.8 $ 6.2 $ (2.9) Total € 238.8 € 238.8 $ 6.2 $ (2.9)

Loss Per Share (Tables)

Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Reconciliation of Numerator and Denominator	A reconciliation of the numerator and denominator used in the calculation of basic and diluted loss per common share is as follows (in millions, except per share amounts): Three Months Ended March 31, Three Months Ended March 31, 2024 2023 Net loss attributable to Mirion Technologies, Inc. shareholders $ (25.8) $ (41.9) Weighted average common shares outstanding – basic and diluted 199.729 187.701 Net loss per common share attributable to Mirion Technologies, Inc. — basic and diluted $ (0.13) $ (0.22)

Restructuring (Tables)

Restructuring (Tables)	3 Months Ended
	Mar. 31, 2024
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve by Type of Cost	The Company’s restructuring expenses are comprised of the following (in millions): Three Months Ended March 31, 2024 Cost of revenue Selling, general Total Severance and employee costs $ — $ — $ — Other (1) — — — Total $ — $ — $ — Three Months Ended March 31, 2023 Cost of revenue Selling, general Total Severance and employee costs $ — $ 1.2 $ 1.2 Other (1) — 0.2 0.2 Total $ — $ 1.4 $ 1.4 (1)
Schedule of Restructuring and Related Costs	The following table summarizes restructuring expenses for each reportable segment (in millions): Three Months Ended March 31, 2024 2023 Restructuring expenses: Medical $ — $ 0.3 Technologies — 0.1 Corporate and other — 1.0 Total $ — $ 1.4

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The components of accumulated other comprehensive loss, net of tax, consist of the following (in millions): March 31, 2024 December 31, 2023 Cumulative foreign currency translation adjustment, net of tax $ (67.0) $ (52.4) Unrealized gain on pension and postretirement benefit plans, net of tax 2.0 2.0 Unrealized loss on net investment hedges, net of tax (13.1) (17.9) Unrealized gain on cash flow hedges, net of tax 0.7 0.1 Less: cumulative loss attributable to noncontrolling interests (3.2) (2.9) Accumulated other comprehensive loss $ (74.2) $ (65.3)

Nature of Business and Summar_4

Nature of Business and Summary of Significant Accounting Policies - Additional Information (Detail) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($) segment $ / shares shares	May 20, 2024 $ / shares	Dec. 31, 2023 USD ($)
Summary Of Significant Accounting Policy [Line Items]
Number of operating segments | segment	2
Number of reportable segments | segment	2
Allowance for doubtful accounts	$ 8.1		$ 7.8
Remaining performance obligations	$ 840.5		857.1
Unredeemed Public Warrants | Forecast
Summary Of Significant Accounting Policy [Line Items]
Warrant exercise price (in dollars per share) | $ / shares		$ 0.10
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-04-01
Summary Of Significant Accounting Policy [Line Items]
Revenue from remaining performance obligation (as a percent)	45%
Revenue, remaining performance obligation, expected timing of satisfaction, period	9 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Summary Of Significant Accounting Policy [Line Items]
Revenue from remaining performance obligation (as a percent)	25%
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Summary Of Significant Accounting Policy [Line Items]
Revenue from remaining performance obligation (as a percent)	12%
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01
Summary Of Significant Accounting Policy [Line Items]
Revenue from remaining performance obligation (as a percent)	10%
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Deferred income taxes and other liabilities
Summary Of Significant Accounting Policy [Line Items]
Asset retirement obligation	$ 2.3		$ 2.3
Class A Common Stock
Summary Of Significant Accounting Policy [Line Items]
Class of warrant or right, shares callable (in shares) | shares	27,249,779
Warrant exercise price (in dollars per share) | $ / shares	$ 11.50

Nature of Business and Summar_5

Nature of Business and Summary of Significant Accounting Policies - Schedule of Other Current Assets (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Prepaid insurance	$ 2.3	$ 1
Prepaid vendor deposits	7.3	7.6
Prepaid software licenses	3.9	3.5
Short-term marketable securities	5.4	5.3
Income tax receivable and prepaid income taxes	1	8
Other tax receivables	1.4	1.4
Other current assets	17.2	17.3
Prepaid expenses and other current assets	$ 38.5	$ 44.1

Business Combinations and Acq_2

Business Combinations and Acquisitions - Narrative (Details) - USD ($) $ in Millions		3 Months Ended
	Nov. 01, 2023	Mar. 31, 2024	Dec. 31, 2023
Business Combination, Separately Recognized Transactions [Line Items]
Goodwill		$ 1,440.2	$ 1,447.6
EC5
Business Combination, Separately Recognized Transactions [Line Items]
Payments to acquire businesses gross	$ 31.4
Recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles	14.5
Goodwill	17.4
Recognized identifiable assets acquired and liabilities assumed, liabilities	$ 0.5
Goodwill, purchase accounting adjustments		0.6
Additional consideration		1
Adjustment, intangibles		$ 0.3

Contracts in Progress - Schedul

Contracts in Progress - Schedule of Cost and Billings on Uncompleted Construction Contracts (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Costs incurred on contracts (from inception to completion)	$ 353.1	$ 324.5
Estimated earnings	211.8	208.7
Contracts in progress	564.9	533.2
Less: billings to date	(524.3)	(511.3)
Contract with customer, asset (liability), net	$ 40.6	$ 21.9

Contracts in Progress - Sched_2

Contracts in Progress - Schedule of Uncompleted Contracts (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Costs and estimated earnings in excess of billings on uncompleted contracts – current	$ 62.6	$ 48.7
Costs and estimated earnings in excess of billings on uncompleted contracts – non-current	11.3	18.2
Billings in excess of costs and estimated earnings on uncompleted contracts – current	(31.5)	(41.1)
Billings in excess of costs and estimated earnings on uncompleted contracts – non-current	(1.8)	(3.9)
Contract with customer, asset (liability), net	$ 40.6	$ 21.9

Contracts in Progress - Narrati

Contracts in Progress - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)
Revenue from Contract with Customer [Abstract]
Contract with customer, liability, revenue recognized	$ 17.6

Inventories - Schedule of Inven

Inventories - Schedule of Inventory (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 66.5	$ 67.2
Work in progress	36.7	35.3
Finished goods	43.6	41.6
Inventories	$ 146.8	$ 144.1

Property, Plant, and Equipmen_3

Property, Plant, and Equipment, Net - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 200.1	$ 191.1
Less: accumulated depreciation and amortization	(61.8)	(56.6)
Property, plant and equipment, net	138.3	134.5
Land, buildings, and leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	49.9	49.4
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	39.6	38.5
Badges
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	44.2	41
Furniture, fixtures, computer equipment and other
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	22.9	22.9
Software development costs
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	11	10.7
Construction in progress (1)
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	32.5	28.6
Software Development
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 5.6	$ 4.2
Minimum | Land, buildings, and leasehold improvements
Property, Plant and Equipment [Line Items]
Depreciable Lives	3 years
Minimum | Machinery and equipment
Property, Plant and Equipment [Line Items]
Depreciable Lives	5 years
Minimum | Badges
Property, Plant and Equipment [Line Items]
Depreciable Lives	3 years
Minimum | Furniture, fixtures, computer equipment and other
Property, Plant and Equipment [Line Items]
Depreciable Lives	3 years
Minimum | Software development costs
Property, Plant and Equipment [Line Items]
Depreciable Lives	3 years
Maximum | Land, buildings, and leasehold improvements
Property, Plant and Equipment [Line Items]
Depreciable Lives	39 years
Maximum | Machinery and equipment
Property, Plant and Equipment [Line Items]
Depreciable Lives	15 years
Maximum | Badges
Property, Plant and Equipment [Line Items]
Depreciable Lives	5 years
Maximum | Furniture, fixtures, computer equipment and other
Property, Plant and Equipment [Line Items]
Depreciable Lives	10 years
Maximum | Software development costs
Property, Plant and Equipment [Line Items]
Depreciable Lives	5 years

Property, Plant, and Equipmen_4

Property, Plant, and Equipment, Net - Schedule of Depreciation Expense (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cost of revenues
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 5.3	$ 4.7
Operating expenses
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 2	$ 2.9

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Accrued Expenses and Other Current Liabilities [Abstract]
Compensation and related benefit costs	$ 34.7	$ 41.8
Customer deposits	8	8.5
Accrued commissions	0.3	0.3
Accrued warranty costs	4.9	4.5
Non-income taxes payable	9.2	11.8
Pension and other post-retirement obligations	0.3	0.3
Income taxes payable	2.7	4.2
Accrued expenses and other current liabilities	7.7	10.7
Other accrued expenses	11.2	13.5
Total accrued expenses and other current liabilities	$ 79	$ 95.6

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Narrative (Details)	3 Months Ended
	Mar. 31, 2024 USD ($)
Goodwill [Line Items]
Goodwill, impairment loss	$ 0

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Schedule of Goodwill (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 1,440.2	$ 1,447.6
Measurement period adjustment	0.6
Translation adjustment	(8)
Goodwill, ending balance	1,440.2
Gross Carrying Amount	1,652	1,659.4
Cumulative Impairment	(211.8)	(211.8)
Medical
Goodwill [Roll Forward]
Goodwill, beginning balance	634	633.4
Measurement period adjustment	0.6
Translation adjustment	0
Goodwill, ending balance	634
Technologies
Goodwill [Roll Forward]
Goodwill, beginning balance	806.2	$ 814.2
Measurement period adjustment	0
Translation adjustment	(8)
Goodwill, ending balance	$ 806.2

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Schedule of Finite-Lived Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 836.6	$ 841.5
Accumulated Amortization	(332.3)	(302.7)
Net Book Value	504.3	538.8
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	339.2	340.8
Accumulated Amortization	(155.8)	(143.1)
Net Book Value	183.4	197.7
Distributor relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	60.9	60.9
Accumulated Amortization	(17.8)	(16)
Net Book Value	43.1	44.9
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	262.3	264.1
Accumulated Amortization	(75.1)	(67.8)
Net Book Value	187.2	196.3
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	99	99.7
Accumulated Amortization	(24.4)	(22.1)
Net Book Value	74.6	77.6
Backlog and other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	75.2	76
Accumulated Amortization	(59.2)	(53.7)
Net Book Value	$ 16	$ 22.3
Minimum | Customer relationships
Finite-Lived Intangible Assets [Line Items]
Original Average Life in Years	6 years	6 years
Minimum | Distributor relationships
Finite-Lived Intangible Assets [Line Items]
Original Average Life in Years	7 years	7 years
Minimum | Developed technology
Finite-Lived Intangible Assets [Line Items]
Original Average Life in Years	5 years	5 years
Minimum | Trade names
Finite-Lived Intangible Assets [Line Items]
Original Average Life in Years	3 years	3 years
Minimum | Backlog and other
Finite-Lived Intangible Assets [Line Items]
Original Average Life in Years	1 year	1 year
Maximum | Customer relationships
Finite-Lived Intangible Assets [Line Items]
Original Average Life in Years	13 years	13 years
Maximum | Distributor relationships
Finite-Lived Intangible Assets [Line Items]
Original Average Life in Years	13 years	13 years
Maximum | Developed technology
Finite-Lived Intangible Assets [Line Items]
Original Average Life in Years	16 years	16 years
Maximum | Trade names
Finite-Lived Intangible Assets [Line Items]
Original Average Life in Years	10 years	10 years
Maximum | Backlog and other
Finite-Lived Intangible Assets [Line Items]
Original Average Life in Years	4 years	4 years

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Schedule of Finite-lived Intangible Assets Amortization Expense (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cost of revenues
Finite-Lived Intangible Assets [Line Items]
Amortization expense for intangible assets in:	$ 6.8	$ 6.7
Operating expenses
Finite-Lived Intangible Assets [Line Items]
Amortization expense for intangible assets in:	$ 24.7	$ 26.9

Borrowings - Schedule of Third

Borrowings - Schedule of Third Party Notes Payable (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Long-Term Debt, Gross	$ 697.3	$ 698.4
Long-Term Debt, Current Maturities	(0.1)	(1.2)
Debt Issuance Costs, Net	(11.8)	(12.5)
Long-Term Debt, Excluding Current Maturities	685.4	684.7
Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Long-Term Debt, Gross	1.7	2.8
2021 Credit Agreement
Debt Instrument [Line Items]
Long-Term Debt, Gross	694.6	694.6
Canadian Financial Institution [Member]
Debt Instrument [Line Items]
Long-Term Debt, Gross	$ 1	$ 1

Borrowings - Narrative (Details

Borrowings - Narrative (Details) € in Millions, $ in Millions		3 Months Ended		12 Months Ended
	Oct. 20, 2021 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	Mar. 31, 2024 EUR (€)	Dec. 31, 2023 EUR (€)	May 31, 2019 USD ($)	May 31, 2019 CAD ($)
Debt Instrument [Line Items]
Long-term debt		$ 685,500,000
Repayments of term loan		125,000,000	$ 125,000,000
Loss on debt extinguishment		0	2,600,000
Debt instrument, overdraft facilities amount		0		$ 0
Accounts receivable, held-for-sale		8,200,000		13,600,000	€ 7.6	€ 12.3
Other short-term borrowings		0		1,000,000
Letter of Credit
Debt Instrument [Line Items]
Line of credit facility, current borrowing capacity		83,200,000		79,300,000	77.1	71.8
Long-term line of credit		59,300,000		60,400,000	€ 54.9	€ 54.7
Restricted cash		$ 1,500,000		1,700,000
Letter of Credit | Minimum
Debt Instrument [Line Items]
Interest rate		0.50%			0.50%
Letter of Credit | Maximum
Debt Instrument [Line Items]
Interest rate		2%			2%
2021 Credit Agreement | Level 2
Debt Instrument [Line Items]
Fair market value of credit agreement		$ 695,500,000		695,500,000
2021 Credit Agreement | Secured Debt
Debt Instrument [Line Items]
Loan amount	$ 830,000,000
Loan term	7 years
Repayments of term loan				127,100,000
Long-term debt		$ 694,600,000		$ 694,600,000
Debt instrument, quarterly repayment, percentage		0.25%			0.25%
Debt issuance costs	$ 21,700,000
2021 Credit Agreement | Secured Debt | Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Debt instrument, adjustment rate	0.50%
Debt instrument, basis spread on variable rate	2.75%
2021 Credit Agreement | Secured Debt | Adjusted SOFR
Debt Instrument [Line Items]
Interest rate		8.36%		8.40%	8.36%	8.40%
2021 Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Loan amount	$ 90,000,000
Line of credit facility, unused capacity, commitment fee percentage	0.50%	0.25%
Line of credit facility, stepdowns, commitment fee percentage	0.375%
Line of credit facility, commitment fee percentage	0.25%
Leverage ratio	7
Revolving credit facility of exceed revolving credit commitment, percentage	40%
Loan term		5 years			5 years
Remaining borrowing capacity		$ 73,600,000		$ 73,600,000
Debt issuance costs	$ 1,800,000
Amortization expense		$ 700,000	$ 3,500,000
2021 Credit Agreement | Revolving Credit Facility | Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Debt instrument, adjustment rate		0%
Debt instrument, basis spread on variable rate		2.75%
2021 Credit Agreement | Letter of Credit
Debt Instrument [Line Items]
Long-term debt		$ 0		0
Maximum borrowing capacity		$ 16,400,000		$ 16,400,000
Canadian Financial Institution [Member]
Debt Instrument [Line Items]
Loan amount							$ 1,300,000	$ 1.7
Interest rate							4.69%	4.69%

Borrowings - Schedule of Contra

Borrowings - Schedule of Contractual Principal Payments (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Long-term Debt, Fiscal Year Maturity [Abstract]
Remainder of 2024	$ 0.1
2025	0.1
2026	1.7
2027	0.1
2028	694.7
Thereafter	0.6
Gross Payments	697.3	$ 698.4
Unamortized debt issuance costs	(11.8)	$ (12.5)
Total third-party borrowings, net of debt issuance costs	$ 685.5

Leased Assets - Narrative (Deta

Leased Assets - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Lessee, Lease, Description [Line Items]
Operating lease, cost	$ 2.7	$ 2.7
Operating lease, payments	2.1	2.6
Right-of-use asset obtained in exchange for operating lease liability	$ 0	$ 0.2
Minimum
Lessee, Lease, Description [Line Items]
Lessee, operating lease, remaining lease term	1 month
Lessee, operating lease, renewal term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Lessee, operating lease, remaining lease term	30 years
Lessee, operating lease, renewal term	10 years

Leased Assets - Schedule of Ope

Leased Assets - Schedule of Operating Lease Assets and Liabilities on Balance Sheet (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Operating lease assets	$ 31.1	$ 32.8
Financing lease assets	0.1	0.1
Current operating lease liabilities	6.6	6.8
Non-current operating lease liabilities	26.5	28.1
Total operating lease liabilities:	33.1	34.9
Current financing lease liabilities	0.1	0.1
Non-current financing lease liabilities	0.1	0.1
Total financing lease liabilities:	$ 0.2	$ 0.2
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other assets	Other assets
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued expenses and other current liabilities	Accrued expenses and other current liabilities
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Deferred income taxes, non-current	Deferred income taxes, non-current

Leased Assets - Schedule of Wei

Leased Assets - Schedule of Weighted Average Lease Term and Discount Rate for Operating Lease (Details)	Mar. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Weighted average remaining lease term (in years)	6 years 6 months	6 years 7 months 6 days
Weighted average discount rate	4.32%	4.32%

Leased Assets - Schedule of Und

Leased Assets - Schedule of Undiscounted Future Minimum Lease Payments (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Leases [Abstract]
2024	$ 5.9
2025	6.9
2026	5.9
2027	5.1
2028	3.9
2029 and thereafter	10.2
Total undiscounted future minimum lease payments	37.9
Less: Imputed interest	(4.8)
Total operating lease liabilities	$ 33.1	$ 34.9

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Unconditional Purchase Obligations (Details) $ in Millions	Mar. 31, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2024	$ 45.6
2025	9.5
2026	1.1
2027	0.6
2028 and thereafter	0
Total	$ 56.8

Commitments and Contingencies_2

Commitments and Contingencies - Narrative (Details) - USD ($) $ in Millions	1 Months Ended
	Oct. 31, 2023	Jun. 30, 2023	Apr. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Damages sought, value	$ 21	$ 10.2	$ 19.3
Damages subject to daily penalty accrual	18
Damages subject to contractual cap, value	$ 14

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Effective income tax rate reconciliation, percent	(4.70%)	2.50%

Supplemental Disclosures to C_3

Supplemental Disclosures to Condensed Consolidated Statements of Cash Flows - Schedule of Cash Flow, Supplemental Disclosures (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Cash Paid For:
Cash paid for interest	$ 14.8	$ 13.9
Cash paid for income taxes	2.8	2.8
Non-Cash Investing and Financing Activities:
Property, plant, and equipment purchases in accrued expense and other liabilities	1.9	0.2
Property, plant, and equipment purchases in accounts payable	1.3	1.6
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	120.2		$ 128.8
Restricted cash—current	0.4		0.6
Restricted cash—non-current	1.1		1.1
Total cash, cash equivalents, and restricted cash	$ 121.7	$ 90.1	$ 130.5	$ 75

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Millions			3 Months Ended
	Oct. 20, 2021	Jun. 17, 2021	Mar. 31, 2024	Mar. 31, 2023	Jan. 01, 2024	Dec. 31, 2023	Oct. 19, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares outstanding (in shares)			18,750,000
Stock-based compensation expense			$ 0.9	$ 4
Profit interests, percent		50%
Profit Interest 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Profit interests (in shares)		3,200,000
Profits interest, threshold price (in dollars per share)	$ 12	$ 12
Profit Interest 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Profit interests (in shares)		2,000,000
Profits interest, threshold price (in dollars per share)	14	$ 14
Profit Interest 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Profit interests (in shares)		3,000,000
Profits interest, threshold price (in dollars per share)	$ 16	$ 16
Board of Directors Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued (in shares)		4,200,000
Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued (in shares)		3,200,000
Chief Financial Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued (in shares)		700,000
Nonemployee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense			$ 0.2	$ 0.2
Vesting Condition, TSR Percentile, Range 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Adjusted cash flow, interpolated achievement, percent				30%
Vesting Condition, TSR Percentile, Range 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Adjusted cash flow, interpolated achievement, percent				80%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of trading days for determining the value per share	20 days	20 days	20 days
Minimum | Vesting Condition, TSR Percentile, Range 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Adjusted cash flow, interpolated achievement, percent				30%
Minimum | Vesting Condition, TSR Percentile, Range 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Adjusted cash flow, interpolated achievement, percent				56%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of trading days for determining the value per share	30 days	30 days	30 days
Maximum | Vesting Condition, TSR Percentile, Range 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Adjusted cash flow, interpolated achievement, percent				55%
Maximum | Vesting Condition, TSR Percentile, Range 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Adjusted cash flow, interpolated achievement, percent				80%
Maximum | Vesting Condition, Organic Revenue Growth, Range 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage				100%
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant (in shares)			548,939	695,351
Restricted Stock Units (RSUs) | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service period			3 years	3 years
Restricted Stock Units (RSUs) | Minimum | Share-based Payment Arrangement, Tranche 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage			33.33%
Restricted Stock Units (RSUs) | Minimum | Share-based Payment Arrangement, Tranche 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage			33.33%
Restricted Stock Units (RSUs) | Minimum | Share-based Payment Arrangement, Tranche 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage			33.33%
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant (in shares)			453,560	233,165
Performance Shares | Adjusted EBITDA
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance condition one			50%
Performance Shares | Vesting Condition Range 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Adjusted EBITDA, interpolated achievement milestone, percent			0%
Adjusted EBITDA			$ 250
Performance Shares | Adjusted Cash Flow
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance condition two			50%
Performance Shares | Vesting Condition, Adjusted Cash Flow, Range 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Adjusted cash flow, interpolated achievement, percent			0%
Adjusted cash flow			$ 525
Performance Shares | TSR Vesting Condition
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance condition one				50%
Performance Shares | Vesting Condition, TSR Percentile, Range 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage				0%
Total shareholder return, percentile			(10.00%)
Vesting threshold, total shareholder return percentile			30%
Performance Shares | Vesting Condition, TSR Percentile, Range 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shareholder return, percentile			0%
Performance Shares | Vesting Condition, TSR Percentile, Range 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shareholder return, percentile			10%
Performance Shares | Vesting Condition, TSR Percentile, Range 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage				200%
Total shareholder return, percentile			10%
Vesting threshold, total shareholder return percentile			80%
Performance Shares | Organic Revenue Vesting Condition
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance condition two		50%
Performance Shares | Vesting Condition, Organic Revenue Growth, Range 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Organic revenue growth percentage				7%
Performance Shares | Minimum | Vesting Condition Range 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Adjusted EBITDA, interpolated achievement milestone, percent			50%
Adjusted EBITDA			$ 250
Performance Shares | Minimum | Vesting Condition Range 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Adjusted EBITDA, interpolated achievement milestone, percent			100%
Adjusted EBITDA			$ 265
Performance Shares | Minimum | Vesting Condition, Adjusted Cash Flow, Range 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Adjusted cash flow, interpolated achievement, percent			50%
Adjusted cash flow			$ 525
Performance Shares | Minimum | Vesting Condition, Adjusted Cash Flow, Range 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Adjusted cash flow, interpolated achievement, percent			100%
Adjusted cash flow			$ 575
Performance Shares | Minimum | Vesting Condition, TSR Percentile, Range 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage				50%
Vesting threshold, total shareholder return percentile			30%
Performance Shares | Minimum | Vesting Condition, TSR Percentile, Range 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage				100%
Vesting threshold, total shareholder return percentile			56%
Performance Shares | Minimum | Vesting Condition, Organic Revenue Growth, Range 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Organic revenue growth percentage				0%
Performance Shares | Minimum | Vesting Condition, Organic Revenue Growth, Range 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage				50%
Organic revenue growth percentage				3%
Performance Shares | Minimum | Vesting Condition, Organic Revenue Growth, Range 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage				100%
Organic revenue growth percentage				5%
Performance Shares | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage			200%	200%
Performance Shares | Maximum | Vesting Condition Range 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Adjusted EBITDA, interpolated achievement milestone, percent			100%
Adjusted EBITDA			$ 265
Performance Shares | Maximum | Vesting Condition Range 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Adjusted EBITDA, interpolated achievement milestone, percent			200%
Adjusted EBITDA			$ 280
Performance Shares | Maximum | Vesting Condition, Adjusted Cash Flow, Range 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Adjusted cash flow, interpolated achievement, percent			100%
Adjusted cash flow			$ 575
Performance Shares | Maximum | Vesting Condition, Adjusted Cash Flow, Range 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Adjusted cash flow, interpolated achievement, percent			200%
Adjusted cash flow			$ 625
Performance Shares | Maximum | Vesting Condition, TSR Percentile, Range 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage				100%
Vesting threshold, total shareholder return percentile			55%
Performance Shares | Maximum | Vesting Condition, TSR Percentile, Range 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage				200%
Vesting threshold, total shareholder return percentile			80%
Performance Shares | Maximum | Vesting Condition, Organic Revenue Growth, Range 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Organic revenue growth percentage				3%
Performance Shares | Maximum | Vesting Condition, Organic Revenue Growth, Range 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Organic revenue growth percentage				5%
Performance Shares | Maximum | Vesting Condition, Organic Revenue Growth, Range 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage				200%
Organic revenue growth percentage				7%
Class A Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)					38,492,328		19,952,329
Common stock outstanding, ownership percentage							3%
Common stock, shares outstanding (in shares)	18,750,000		218,735,333			218,177,832	9,976,164
Stock-based compensation expense			$ 2.6	$ 1.6
Class A Common Stock | Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense			$ 0.1	$ 0.1

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions			3 Months Ended
	Oct. 20, 2021	Jun. 17, 2021	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Oct. 19, 2021
Related Party Transaction [Line Items]
Common stock, shares outstanding (in shares)			18,750,000
Issuance of shares of class A common stock, net of offering costs				$ 149.8
Transfer of membership interests to certain individuals (in shares)	8,100,000
Related Party
Related Party Transaction [Line Items]
Working capital note amount			$ 0	$ 0.6
Related Party | Private Placement
Related Party Transaction [Line Items]
Class of warrant or right outstanding (in shares)	8,500,000
Share price (in dollars per share)	$ 2
Issuance of shares of class A common stock, net of offering costs	$ 17
Number of securities called by each warrant or right (in shares)	1
Warrant exercise price (in dollars per share)	$ 11.50
Minimum
Related Party Transaction [Line Items]
Number of trading days for determining the value per share	20 days	20 days	20 days
Maximum
Related Party Transaction [Line Items]
Number of trading days for determining the value per share	30 days	30 days	30 days
Profit Interest 1
Related Party Transaction [Line Items]
Profits interest, threshold price (in dollars per share)	$ 12	$ 12
Profit Interest 2
Related Party Transaction [Line Items]
Profits interest, threshold price (in dollars per share)	14	14
Profit Interest 3
Related Party Transaction [Line Items]
Profits interest, threshold price (in dollars per share)	$ 16	$ 16
Class B Common Stock
Related Party Transaction [Line Items]
Common stock, shares outstanding (in shares)	18,750,000		7,326,423		7,787,333
Class A Common Stock
Related Party Transaction [Line Items]
Common stock, shares outstanding (in shares)	18,750,000		218,735,333		218,177,832	9,976,164
Class of warrant or right outstanding (in shares)			27,249,779
Number of securities called by each warrant or right (in shares)			1
Warrant exercise price (in dollars per share)			$ 11.50

Segment Information - Schedule

Segment Information - Schedule of Segment Reporting Information, by Segment (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Segment Reporting Information [Line Items]
Total revenues	$ 192.6	$ 182.1
Loss from operations	(4.9)	(13.6)
Medical
Segment Reporting Information [Line Items]
Total revenues	66.8	66.4
Technologies
Segment Reporting Information [Line Items]
Total revenues	125.8	115.7
Operating Segments
Segment Reporting Information [Line Items]
Loss from operations	14	6.2
Operating Segments | Medical
Segment Reporting Information [Line Items]
Loss from operations	1.4	0.7
Operating Segments | Technologies
Segment Reporting Information [Line Items]
Loss from operations	12.6	5.5
Corporate and other
Segment Reporting Information [Line Items]
Loss from operations	$ (18.9)	$ (19.8)

Segment Information - Revenue f

Segment Information - Revenue from External Customers by Geographic Areas (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 192.6	$ 182.1
Medical
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	66.8	66.4
Technologies
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	125.8	115.7
North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	119	115.9
North America | Medical
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	60.4	60.7
North America | Technologies
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	58.6	55.2
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	67.8	58.8
Europe | Medical
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	6.4	5.7
Europe | Technologies
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	61.4	53.1
Asia Pacific
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	5.8	7.4
Asia Pacific | Medical
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	0	0
Asia Pacific | Technologies
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 5.8	$ 7.4

Segment Information - Schedul_2

Segment Information - Schedule of Revenue by Timing of Recognition (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue, Major Customer [Line Items]
Total revenues	$ 192.6	$ 182.1
Point in time
Revenue, Major Customer [Line Items]
Total revenues	126.9	118.3
Over time
Revenue, Major Customer [Line Items]
Total revenues	$ 65.7	$ 63.8

Segment Information - Revenue_2

Segment Information - Revenue from External Customers by Products and Services (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue from External Customer [Line Items]
Total revenues	$ 192.6	$ 182.1
Medical
Revenue from External Customer [Line Items]
Total revenues	66.8	66.4
Technologies
Revenue from External Customer [Line Items]
Total revenues	125.8	115.7
Medical | Medical
Revenue from External Customer [Line Items]
Total revenues	66.8	66.4
Reactor Safety and Control Systems | Technologies
Revenue from External Customer [Line Items]
Total revenues	50.3	42.1
Radiological Search, Measurement, and Analysis Systems | Technologies
Revenue from External Customer [Line Items]
Total revenues	$ 75.5	$ 73.6

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value (Detail) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Liabilities
Warrant liabilities	$ 61	$ 55.3
Fair Value, Recurring | Level 1
Assets
Cash, cash equivalents, and restricted cash	121.7	130.5
Discretionary retirement plan	4.1	4
Liabilities
Discretionary Retirement Plan Liabilities, Fair Value Disclosure	4.1	4
Derivative liability	0	0
Fair Value, Recurring | Level 1 | Public warrants
Liabilities
Warrant liabilities	42	38.1
Fair Value, Recurring | Level 1 | Private placement warrants
Liabilities
Warrant liabilities	0	0
Fair Value, Recurring | Level 1 | Cross-Currency Rate Swaps
Assets
Derivative asset	0	0
Fair Value, Recurring | Level 1 | Interest Rate Swap
Assets
Derivative asset	0	0
Fair Value, Recurring | Level 2
Assets
Cash, cash equivalents, and restricted cash	0	0
Discretionary retirement plan	1	1
Liabilities
Discretionary Retirement Plan Liabilities, Fair Value Disclosure	1	1
Derivative liability	17.1	23.3
Fair Value, Recurring | Level 2 | Public warrants
Liabilities
Warrant liabilities	0	0
Fair Value, Recurring | Level 2 | Private placement warrants
Liabilities
Warrant liabilities	19	17.3
Fair Value, Recurring | Level 2 | Cross-Currency Rate Swaps
Assets
Derivative asset	0.1	0.1
Fair Value, Recurring | Level 2 | Interest Rate Swap
Assets
Derivative asset	0.9	0.1
Fair Value, Recurring | Level 3
Assets
Cash, cash equivalents, and restricted cash	0	0
Discretionary retirement plan	0	0
Liabilities
Discretionary Retirement Plan Liabilities, Fair Value Disclosure	0	0
Derivative liability	0	0
Fair Value, Recurring | Level 3 | Public warrants
Liabilities
Warrant liabilities	0	0
Fair Value, Recurring | Level 3 | Private placement warrants
Liabilities
Warrant liabilities	0	0
Fair Value, Recurring | Level 3 | Cross-Currency Rate Swaps
Assets
Derivative asset	0	0
Fair Value, Recurring | Level 3 | Interest Rate Swap
Assets
Derivative asset	$ 0	$ 0

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Increase in fair values of warrant liabilities	$ 5.7	$ 13.4

Derivatives and Hedging - Narra

Derivatives and Hedging - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)
Cash Flow Hedging
Derivative [Line Items]
Maximum exposure hedging duration	3 years
Interest Rate Swap
Derivative [Line Items]
Notional Amount	$ 75
OCI, cash flow hedge, before reclassification	0.8
Interest Rate Swap | Interest Expense
Derivative [Line Items]
Other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax	$ 0.3

Derivatives and Hedging - Sched

Derivatives and Hedging - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Derivative [Line Items]
Accrued expenses and other current liabilities	$ 7.7	$ 10.7
Derivatives Designated as Hedging Instruments
Derivative [Line Items]
Total assets	1	0.2
Total liabilities	17.2	23.3
Cross-Currency Rate Swaps | Derivatives Designated as Hedging Instruments
Derivative [Line Items]
Prepaid expenses and other currents assets	0.1	0.1
Accrued expenses and other current liabilities	7.7	10.7
Other non-current liabilities	9.5	12.6
Interest Rate Swap | Derivatives Designated as Hedging Instruments
Derivative [Line Items]
Other non-current assets	$ 0.9	$ 0.1

Derivatives and Hedging - Sch_2

Derivatives and Hedging - Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) (Details) € in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2024 EUR (€)	Dec. 31, 2023 USD ($)
Net Investment Hedging
Derivative [Line Items]
Notional Amount			€ 238.8	$ 238.8
Gain (Loss) Recognized in AOCL	$ 6.2	$ (2.9)
Cross-Currency Rate Swaps | Net Investment Hedging
Derivative [Line Items]
Notional Amount			€ 238.8	$ 238.8
Gain (Loss) Recognized in AOCL	6.2	$ (2.9)
Interest Rate Swap
Derivative [Line Items]
Notional Amount	$ 75

Loss Per Share - Reconciliation

Loss Per Share - Reconciliation of Numerator and Denominator (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Net loss attributable to Mirion Technologies, Inc. shareholders	$ (25.8)	$ (41.9)
Weighted average common shares outstanding — basic (in shares)	199,729	187,701
Weighted average common shares outstanding — diluted (in shares)	199,729	187,701
Net loss per common share attributable to Mirion Technologies, Inc. — diluted (in dollars per share)	$ (0.13)	$ (0.22)
Net loss per common share attributable to Mirion Technologies, Inc. — basic (in dollars per share)	$ (0.13)	$ (0.22)
Share-based awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	2,577	687

Loss Per Share - Narrative (Det

Loss Per Share - Narrative (Details)			3 Months Ended
	Oct. 20, 2021 vote shares	Jun. 17, 2021	Mar. 31, 2024 vote tranche $ / shares shares	Dec. 31, 2023 shares	Oct. 19, 2021 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period			5 years
Number of tranches | tranche			3
Common stock, shares outstanding (in shares)			18,750,000
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of trading days for determining the value per share	20 days	20 days	20 days
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of trading days for determining the value per share	30 days	30 days	30 days
Share-based Payment Arrangement, Tranche 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant-date fair value, granted (dollars per share) | $ / shares			$ 12
Share-based Payment Arrangement, Tranche 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant-date fair value, granted (dollars per share) | $ / shares			14
Share-based Payment Arrangement, Tranche 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant-date fair value, granted (dollars per share) | $ / shares			$ 16
Class A Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, number of votes per common share | vote			1
Class of warrant or right outstanding (in shares)			27,249,779
Number of securities called by each warrant or right (in shares)			1
Warrant exercise price (in dollars per share) | $ / shares			$ 11.50
Common stock, shares outstanding (in shares)	18,750,000		218,735,333	218,177,832	9,976,164
Class A Common Stock | Public warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right outstanding (in shares)			18,749,779
Class A Common Stock | Private placement warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right outstanding (in shares)			8,500,000
Class B Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, number of votes per common share | vote	1		1
Common stock, shares outstanding (in shares)	18,750,000		7,326,423	7,787,333

Restructuring - Schedule of Res

Restructuring - Schedule of Restructuring Reserve by Type of Cost (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Restructuring Cost and Reserve [Line Items]
Severance and employee costs	$ 0	$ 1.2
Other	0	0.2
Total	0	1.4
Cost of revenues
Restructuring Cost and Reserve [Line Items]
Severance and employee costs	0	0
Other	0	0
Total	0	0
Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Severance and employee costs	0	1.2
Other	0	0.2
Total	$ 0	$ 1.4

Restructuring - Summary of Rest

Restructuring - Summary of Restructuring Expenses (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Restructuring Cost and Reserve [Line Items]
Total	$ 0	$ 1.4
Operating Segments | Medical
Restructuring Cost and Reserve [Line Items]
Total	0	0.3
Operating Segments | Technologies
Restructuring Cost and Reserve [Line Items]
Total	0	0.1
Corporate and other
Restructuring Cost and Reserve [Line Items]
Total	$ 0	$ 1

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Restructuring and Related Activities [Abstract]
Restructuring reserve, current	$ 0	$ 0

Noncontrolling Interests (Detai

Noncontrolling Interests (Details) $ / shares in Units, $ in Millions		3 Months Ended
	Oct. 20, 2021 vote day $ / shares shares	Mar. 31, 2024 USD ($) vote shares	Dec. 31, 2023 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Noncontrolling Interest [Line Items]
Share-based compensation arrangement by share-based payment award, fair value assumptions, exercise price (in dollars per share) | $ / shares	$ 10
Debt instrument, convertible, threshold trading days for redemption | day	3
Noncontrolling interest | $		$ 1,517.9	$ 1,550	$ 1,588	$ 1,467.2
Noncontrolling Interests
Noncontrolling Interest [Line Items]
Noncontrolling interest | $		$ 60.7	$ 65.5	$ 66.7	$ 69
IntermediateCo Class A common stock | GSAH
Noncontrolling Interest [Line Items]
Percentage of voting shares	100%
IntermediateCo Class B common stock
Noncontrolling Interest [Line Items]
Shares issued (in shares) | shares	1
Percentage of non-voting share	96%
Percentage of non-voting interests not attributable portion	4%	3.20%
Class B Common Stock
Noncontrolling Interest [Line Items]
Common stock, number of votes per common share | vote	1	1
Common stock, convertible, conversion r.atio	1
Class B Common Stock | Intermediate Co
Noncontrolling Interest [Line Items]
Business acquisition equity interest issued or issuable (in shares) | shares	8,560,540	7,326,423
Class A Common Stock
Noncontrolling Interest [Line Items]
Common stock, number of votes per common share | vote		1
Common stock, convertible, conversion r.atio	1

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Noncontrolling interest	$ 1,517.9	$ 1,550	$ 1,588	$ 1,467.2
Cumulative foreign currency translation adjustment, net of tax
Accumulated Other Comprehensive Income (Loss) [Line Items]
Noncontrolling interest	(67)	(52.4)
Unrealized gain on pension and postretirement benefit plans, net of tax
Accumulated Other Comprehensive Income (Loss) [Line Items]
Noncontrolling interest	2	2
Unrealized loss on net investment hedges, net of tax
Accumulated Other Comprehensive Income (Loss) [Line Items]
Noncontrolling interest	(13.1)	(17.9)
Unrealized gain on cash flow hedges, net of tax
Accumulated Other Comprehensive Income (Loss) [Line Items]
Noncontrolling interest	0.7	0.1
Less: cumulative loss attributable to noncontrolling interests
Accumulated Other Comprehensive Income (Loss) [Line Items]
Noncontrolling interest	(3.2)	(2.9)
Accumulated Other Comprehensive (Loss) Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Noncontrolling interest	$ (74.2)	$ (65.3)	$ (67.7)	$ (75.7)

Subsequent Events (Details)

Subsequent Events (Details) - Forecast	May 20, 2024 $ / shares shares
Public warrants
Subsequent Event [Line Items]
Warrant exercise price (in dollars per share)	$ 11.50
Number of securities called by each warrant or right (in shares) | shares	0.220
Unredeemed Public Warrants
Subsequent Event [Line Items]
Warrant exercise price (in dollars per share)	$ 0.10